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Development and evaluation of a subunit DIVA vaccine against 
bluetongue virus serotype 8 in cattle 
Abstract 
Bluetongue virus (BTV) causes the primarily vector-borne bluetongue disease of 
ruminants, which poses a permanent threat to Europe since new serotypes and strains 
are frequently introduced. Vaccination of cattle is essential to control BTV outbreaks. 
Commercial attenuated and inactivated vaccines are efficacious in reducing BTV 
spread and disease, but do not fulfil all safety, adaptability, or production requirements. 
Additionally, no current vaccines allow the differentiation of infected from vaccinated 
animals (DIVA). DIVA vaccines enable surveillance of BTV epidemiology and 
vaccine efficacy, and facilitate a quick return for countries to a BTV-free status. This 
thesis presents the development and evaluation of a novel subunit DIVA vaccine 
against BTV serotype 8 (BTV-8) in cattle. 
Five His-tagged recombinant BTV proteins (VP2, VP5 of BTV-8; NS1, NS2, NS3 
of BTV-2) were produced in baculovirus or E. coli expression systems. Purification 
protocols were optimized for all but VP5. Based on the feasibility of protein production 
and the capability of the remaining four proteins to induce humoral or cellular immune 
responses in mice, VP2, NS1, and NS2 were selected to formulate an experimental 
vaccine combined to an ISCOM-matrix adjuvant (SubV). 
Next, cattle were immunized twice at a three-week interval with SubV, a commercial 
inactivated vaccine, or a placebo. SubV induced humoral immune responses, including 
virus-neutralizing antibodies, against all three proteins, as well as a cellular immune 
response directed against NS1. These responses were of similar type and comparable 
magnitude between both vaccines, suggesting that SubV might provide protection that 
is at least as effective as the commercial vaccine. Finally, the protective efficacy of 
SubV was evaluated and complete virological and clinical protection against virulent 
BTV-8 challenge was observed following vaccination in calves. This was likely due to 
the induction of virus-neutralizing antibodies directed against VP2 of BTV-8 and cross-
serotype T cell responses directed against NS1 and NS2 of BTV-2. Furthermore, SubV 
was shown to be DIVA-compliant based on the detection of antibodies directed against 
VP7, by using commercially-available diagnostic assays. This novel BTV subunit 
vaccine is a promising candidate and should be further developed. 
Keywords: Bluetongue, virus, cattle, vaccine, subunit, immunogenicity, humoral, 
cellular, protection, DIVA 
Author’s address: Jenna Anderson, SLU, Department of Clinical Sciences,  
P.O. Box 7054, 750 07 Uppsala, Sweden  
E-mail: Jenna.Anderson@slu.se
 Dedication 
To my family,  
and to all friends who form my 
Swedish family 
  
Contents 
List of Publications 9	  
Abbreviations 11	  
1	   Introduction 13	  
1.1	   History 13	  
1.2	   BTV classification and viral characteristics 14	  
1.3	   Epidemiology and transmission 16	  
1.3.1	   Host and vector species 17	  
1.3.2	   Routes of transmission 17	  
1.3.3	   Geographical and seasonal distribution 21	  
1.4	   Host-pathogen interactions 24	  
1.4.1	   Pathogenesis and innate immune response to BTV 24	  
1.4.2	   Protein-specific humoral immune responses 26	  
1.4.3	   Protein-specific cellular immune responses 27	  
1.5	   Clinical signs 30	  
1.5.1	   Clinical signs in small ruminants 30	  
1.5.2	   Clinical signs in cattle 31	  
1.5.3	   Clinical signs in other ruminants 31	  
1.5.4	   BTV infection in carnivores 32	  
1.6	   Diagnosis 32	  
1.6.1	   Virological diagnosis 33	  
1.6.2	   Serological diagnosis 33	  
1.7	   Prevention and control 34	  
1.7.1	   Biosecurity and animal movement control measures 34	  
1.7.2	   Vaccines 35	  
2	   Aims of the thesis 45	  
3	   Materials and methods 47	  
3.1	   Recombinant protein expression and production 47	  
3.2	   Recombinant protein purification 48	  
3.3	   Recombinant protein identification and quantification 50	  
3.4	   Recombinant protein stability analyses 51	  
3.5	   Animals, clinical examinations, and study designs 51	  
3.5.1	   Study I 52	  
3.5.2	   Study II 53	  
 3.5.3	   Study III 54	  
3.6	   Virus detection 57	  
3.6.1	   ECE inoculation 57	  
3.6.2	   RT-qPCR 57	  
3.7	   Humoral immunity analyses 57	  
3.7.1	   Virus neutralizing antibody assay 57	  
3.7.2	   Detection of BTV-8 (VP2)-specific antibodies 58	  
3.7.3	   Detection of BTV-2 NS1-, NS2-, and NS3-specific IgG1  
antibodies 59	  
3.7.4	   Detection of VP7-specific IgG or IgM antibodies for all BTV 
serotypes 60	  
3.8	   Cellular immunity analyses 60	  
3.8.1	   Lymphocyte proliferation analyses 60	  
3.8.2	   Detection of IFN gamma (IFN-γ) production of restimulated 
lymphocytes 61	  
3.9	   Statistical analyses 61	  
4	   Results and discussion 63	  
4.1	   Formulation and optimization of a novel DIVA subunit vaccine against 
BTV-8 63	  
4.1.1	   Production, expression, and quantification of recombinant BTV 
proteins for subunit vaccine design 63	  
4.1.2	   Stability of recombinant BTV proteins 65	  
4.1.3	   Selection of BTV proteins based on their immunogenicity for 
inclusion in experimental subunit vaccine 66	  
4.1.4	   Modulation of adjuvant composition of SubV for cattle 68	  
4.2	   Humoral immune responses against BTV in cattle following vaccination 
and challenge 69	  
4.2.1	   Induction of BTV-8 neutralizing antibody titers in cattle 69	  
4.2.2	   Induction of serum antibodies directed against VP2 (BTV-8) and 
NS1, NS2 (BTV-2) detected by ELISA 70	  
4.3	   Cellular immune responses against BTV in cattle following vaccination 
and challenge 72	  
4.3.1	   Induction of VP2-specific lymphocyte proliferative responses 72	  
4.3.2	   Induction of NS1-, NS2-, and UV-inactivated BTV-8 specific 
lymphocyte proliferative responses 73	  
4.4	   Protective efficacy against BTV-8 challenge 75	  
4.4.1	   Clinical signs following BTV-8 challenge 75	  
4.4.2	   Quantification of BTV RNA and detection of BTV in blood 75	  
4.5	   DIVA compliancy based on serotype-specific and pan-BTV ELISAs 76	  
 5	   Concluding remarks 81	  
6	   Future perspectives 83	  
References 87	  
Acknowledgements 119	  
 
 
 8 
 9 
List of Publications 
This thesis is based on the work contained in the following papers, referred to 
by Roman numerals in the text: 
I Anderson, Jenna; Bréard, Emmanuel; Lövgren Bengtsson, Karin; Grönvik, 
Kjell-Olov; Zientara, Stéphan; Valarcher, Jean-François; and Sara 
Hägglund (2014). Purification, stability, and immunogenicity analyses of 
five bluetongue virus proteins for use in the development of a subunit 
vaccine that allows the differentiation of infected from vaccinated animals. 
Clinical and Vaccine Immunology 21(3), 443-452. 
II Anderson, Jenna; Hägglund, Sara; Bréard, Emmanuel; Lövgren Bengtsson, 
Karin; Pringle, John; Zientara, Stéphan; and Jean-François Valarcher 
(2013). Evaluation of the immunogenicity of an experimental subunit 
vaccine that allows differentiation between infected and vaccinated animals 
against bluetongue virus serotype 8 in cattle. Clinical and Vaccine 
Immunology 20(8), 1115-1122. 
III Anderson, Jenna; Hägglund, Sara; Bréard, Emmanuel; Riou, Mickaël; 
Zohari, Siamak; Comtet, Loic; Olofson, Ann-Sophie; Gélineau, Robert; 
Martin, Guillaume; Elvander, Marianne; Blomqvist, Gunilla; Zientara, 
Stéphan; and Jean-François Valarcher. Strong protection induced by an 
experimental DIVA subunit vaccine against bluetongue virus serotype 8 in 
cattle (submitted manuscript). 
Papers I and II are reproduced with the permission of the publishers. 
 10 
The contribution of JMA to the papers included in this thesis was as follows: 
I Shared author, laboratory work, and analysis of results. Participant in 
animal experiments. 
II Main author and primary contributor to laboratory work. Participant in 
animal experiments. Shared analysis of results.  
III Main author and primary contributor to laboratory work for vaccine 
preparations. Participant in animal experiments. Shared laboratory work 
with samples from vaccinated animals and shared analysis of results.  
 11 
Abbreviations 
 
BHK-21 baby hamster kidney (cells) 
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CV commercial inactivated vaccine 
ddH2O distilled deionized water 
DISC disabled infectious single cycle 
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IFNAR(-/-) type 1 interferon receptor-deficient 
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MEM minimal essential medium 
MHC major histocompatibility complex 
MLVs modified live virus vaccines 
MW molecular weight 
NS non-structural 
OD optical density 
PBMCs peripheral blood mononuclear cells 
RNA ribonucleic acid 
RT room temperature 
RT-PCR reverse transcription-polymerase chain reaction 
RT-qPCR real time quantitative-PCR 
SD standard deviation 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SLU Swedish University of Agricultural Sciences 
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TMB 3,3',5,5-tetramethylbenxidine 
UV ultraviolet radiation 
VIBs viral inclusion bodies 
VLPs virus-like particle vaccines 
VP viral (structural) protein 
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1 Introduction 
When Edward Jenner removed biological material from a cowpox sore on a 
milkmaid, inoculated the gardener's son with it, and showed that the boy was 
protected from serious smallpox infection, he brought the concept of 
vaccination to the forefront in Europe. He also highlighted the natural 
synergism between human and veterinary medicine. In contrast to bacteria, 
against which a wide array of antibiotics have been discovered, we have few 
tools to combat viruses, and in combination with biosecurity measures, 
vaccination remains one of our best methods for preventing and controlling 
many viral diseases. Virus outbreaks in livestock can cause huge economic 
losses and animal welfare concerns, as well as impact food quantity and 
quality. This is exemplified by the recent bluetongue virus (BTV) outbreaks 
within the Europe, which differed from previous experiences and resulted in 
the loss of tens of thousands of animal lives and over 200 million euros in the 
Netherlands alone (Elbers et al., 2009; Velthuis et al., 2010). Additionally, 
European countries that were previously considered BTV-free took on costly 
control measures necessary to regain their BTV-free status. Due to climate- 
and trade-driven factors contributing to the spread of this arbovirus (Purse et 
al., 2005; Beer et al., 2013), BTV is considered a persistently emerging threat 
to the region. In many parts of the world, BTV is endemic and controlled by 
vaccination, but in regions in which the virus is emerging, new considerations 
for vaccines are required since traditional approaches confound surveillance 
and control measures in these areas. In this introduction, I will present BTV as 
well as both traditional and new approaches to vaccination against this virus.  
1.1 History 
Bluetongue (BT) disease is thought to have long existed on the African 
continent, though it has only been described in scientific literature since the 
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late eighteenth century (Spruell, 1905). The virus became of interest following 
the introduction of foreign sheep breeds to southern Africa during the years of 
British and Dutch colonization. Since then, BTV has made numerous 
incursions onto every continent except Antarctica, including North America in 
the 1950s (Hardy & Price, 1952) and Australia in 1975 (Ward, 1994). Since 
outbreaks of the virus are often associated with large economic losses, BTV 
was included from the mid-1960s on the OIE's previous "List A" of notifiable 
diseases. 
Advancements in virology, entomology, and vaccinology have arisen from 
research concerning BTV. For example, in the early 1970s researchers from the 
Onderstepoort Veterinary Institute, South Africa, showed that the BTV genome 
consisted of double-stranded (ds) ribonucleic acid (RNA) (Verwoerd et al., 
1970); a controversial observation at a time when viruses were thought to 
possess only dsDNA (deoxyribonucleic acid) or single-stranded (ss) DNA or 
RNA genomes (Palmarini, 2014). Furthermore, while trying to determine if 
Culicoides insects transmitted BTV or epizootic hemorrhagic disease virus, 
researchers at Onderstepoort improved the design of a light trap to better 
collect midges (Du Toit, 1944), thereby contributing to the field of 
entomology. Additionally, advances in egg-based vaccine attenuation, 
application of lyophilization to vaccine production, and understanding the 
concept of virus serotypes kept BTV on the cutting edge of vaccinology 
throughout the twentieth century (Verwoerd, 2009). 
1.2 BTV classification and viral characteristics 
Bluetongue virus is a non-enveloped RNA virus classified as a Group III virus 
of the family Reoviridae (International Committee on Taxonomy of Viruses, 
2012). It is the type species of the genus Orbivirus, which includes other 
economically important viruses such as African horse sickness virus and 
epizootic hemorrhagic disease virus. Like other orbiviruses, BTV has a dsRNA 
genome composed of ten linear segments of different lengths, surrounded by a 
double-capsid icosahedral shell that is approximately 85 nm in diameter (Gouet 
et al., 1999). The BTV virion consists of twelve known proteins, including 
seven structural viral proteins (VP1-7) that provide the virus’s structure, and 
five non-structural proteins (NS1-4, NS3A), which are produced only during 
infection (Figure 1). 
One hundred and eighty copies of VP2 (molecular weight, MW: 111 kDa) 
and 360 copies of VP5 (MW: 59 kDa) form 60 triskelion and 120 globular 
structures, respectively, that fit together to make up the virus’s outermost 
capsid. The inner BTV capsid is composed of 780 copies (260 trimers) of VP7 
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(MW: 39 kDa), organized as hexameric or pentameric rings and whose 
appearance provides the genus with its name (orbi- for "ring") (International 
Committee on Taxonomy of Viruses, 2012). Within this capsid lies an inner 
layer composed of 120 copies of VP3 (MW: 130 kDa), which in turn encloses 
the three minor structural proteins, VP1 (MW: 150 kDa), VP4 (MW: 76 kDa), 
and VP6 (MW: 36 kDa), as well as the virus's ten dsRNA genome segments. 
Regarding genomic sequence, VP2 and VP5 are the most variable BTV 
proteins (Maan et al., 2008). They act to facilitate attachment (Hassan & Roy, 
1999) and entry into the host cell (Hassan & Roy, 1999; Hassan et al., 2001). 
In particular, VP2 attaches to specific host cell receptors (including likely sialic 
acid and others (Zhang et al., 2010)) to allow receptor-mediated endocytosis 
(Hassan et al., 2001). VP5 has membrane-permeabilizing capabilities due to its 
many amphipathic helix regions, which can destabilize cellular membranes 
following attachment (Hassan et al., 2001; Zhang et al., 2010). 
VP7 is an important structural protein of the virus as it contributes to BTV 
capside assembly (Limn et al., 2000) and also attaches to cell receptors of 
Culicoides vectors (Xu et al., 1997). The protein can bind dsRNA, and 
although the importance of this function is unknown, it may prevent the 
dsRNA from triggering apoptotic responses in infected cells (Diprose et al., 
2002). VP7 defines the BTV serogroup (Huismans & Erasmus, 1981) and is 
highly conserved across several orbiviruses (Oldfield et al., 1990). 
VP1, VP4, and VP6 function as RNA polymerase (Boyce et al., 2004), the 
capping and methyltransferase enzyme (Ramadevi et al., 1998), and helicase 
(Stäuber et al., 1997), respectively. Together, these three proteins are called the 
transcription complex and are located at the vertices of the virion's inner core 
(Gouet et al., 1999). 
The five remaining BTV proteins are NS proteins. NS1 (MW: 64 kDa) 
forms tubules which are characteristic of orbivirus replication (Owens et al., 
2004), plays a role in viral morphogenesis and release from infected cells 
(Eaton et al., 1988), as well as participates in the upregulation of viral protein 
synthesis (Boyce et al., 2012). NS2 (MW: 41 kDa) helps form viral inclusion 
bodies (VIBs), binds ssRNA (Butan & Tucker, 2010), and aids virus 
replication and assembly (Horscroft & Roy, 2000). NS3 and its truncated 
version, NS3A, (MW: 25 and 24 kDa, respectively) are translated from the 
same genome segment and open reading frame (Van Dijk & Huismans, 1988) 
and work with NS1 to facilitate virion release from both insect and mammalian 
cells (Celma & Roy, 2009), perhaps through viroporin activities (Han & Harty, 
2004). The functions of NS4 are less well elucidated since it has only recently 
been identified, but the protein seems to play a role in interactions between 
BTV and the host (Ratinier et al., 2011). 
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Figure 1. Schematic illustration of the BTV virion, including VP1-7 surrounding 10 dsRNA 
genome segments. The genome segment that encodes for each protein is indicated in the chart, as 
are the primary functions of the individual proteins. 
Similar to other reoviruses including epizootic hemorrhagic disease virus, 
BTV is sensitive to temperature (inactivated by 3 h at 50°C or 15 min at 60°C), 
pH less than 6.0 or greater than 8.0, and certain chemicals and disinfectants 
including β-propiolactone, iodophores, and phenolic compounds (OIE, 2013). 
BTV is also sensitive to 254-nm UV radiation and can be inactivated after at 
least 20 min at 2.3 J/cm2 (10-cm distance) (Ruscanu et al., 2012). On the other 
hand, BTV is stable for years in the presence of protein, such as in blood or 
tissue samples, and is more stable at +4°C or -70°C than -20°C (Verwoerd & 
Erasmus, 2004). BTV can also be freeze-dried, for example for vaccine use. 
1.3 Epidemiology and transmission 
BTV epidemiology is described by the geographical distribution of different 
BTV serotypes as well as the presence of potential hosts and vectors. The virus 
neutralizing ability of antibodies that are produced against them determines the 
BTV serotype. This serotype-specificity of antibody production is attributed to 
the outer capsid protein VP2 (Huismans & Erasmus, 1981; Kahlon et al., 1983; 
Roy et al., 1990; Mertens et al., 2007; Maan et al., 2011b) and to some extent 
VP5 (Roy et al., 1990). There are currently 26 BTV serotypes recognized 
worldwide (International Committee on Taxonomy of Viruses, 2012), two of 
which have been identified since the start of this project in 2010 (Hofmann et 
al., 2008; Maan et al., 2011b), plus a potential 27th serotype identified in 
Corsica just two months before printing this thesis (ProMED-mail, 2014). The 
BTV serotypes can be further divided into topotypes by genetic analysis of 
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certain RNA genome segments, such as segment 3 (encoding for VP3) or 
segment 10 (encoding for NS3). These topotypes indicate regional differences 
among serotypes and include "western" (the Americas, Africa, Europe) or 
"eastern" (Asia, Australia) genetic variations (Gould & Pritchard, 1990; 
Bonneau et al., 1999; Balasuriya et al., 2008), though it has been suggested 
that there are likely other topotypes corresponding to additional geographical 
lineages as well (Maan et al., 2012). 
1.3.1 Host and vector species 
All ruminants are potential hosts of BTV, though species and breed, among 
other factors, can play a role in whether BTV infection manifests as clinical 
disease (please see section 1.5). BTV is typically transmitted among 
susceptible hosts through the bite of a competent Culicoides midge. Although 
there are over 1400 recognized species of Culicoides, only approximately 30 
species are known to be competent for transmitting BTV (Aiello & Moses, 
2012). Traditionally, C. imicola is considered the most important species for 
transmitting the virus in Europe, Africa, and the Middle East (Mellor, 2004),  
C. sonorensis (formerly referred to as C. variipennis) in North America 
(Tabachnick, 1996), and C. insignis in Central America (Mo et al., 1994). 
1.3.2 Routes of transmission 
Since BTV is primarily considered a vector-borne virus, its epidemiology is 
strongly linked to the presence of competent vectors. However, in some cases, 
vertical (transplacental) transmission has been implicated for certain strains or 
serotypes (Luedke et al., 1977a; Wouda et al., 2008; Saegerman et al., 2011), 
and there are even recent reports of direct contact transmission of some BTV 
serotypes in goats and cattle (Rasmussen et al., 2013; Batten et al., 2014). 
Vector-borne transmission 
Only female Culicoides midges feed on blood (Mellor et al., 2000) and a single 
bite of an infected midge is sufficient to infect a susceptible sheep (Foster et 
al., 1968). Conversely, the quantity of virus in the host blood considered 
necessary to infect a competent Culicoides midge is relatively low, at 
approximately 2.5-3 log10 TCID50 (50% tissue culture infective dose) per 
milliliter (Fu et al., 1999; Savini et al., 2008). Based on studies primarily 
performed in the United Kingdom and United States using C. variipennis, the 
mechanisms of BTV infection and replication within its vector have been well 
elucidated (Figure 2). Briefly, the transmission of BTV to a susceptible 
ruminant begins with the bite of a competent female midge. The presence of 
trypsin-like proteins in the saliva of competent midges may aid the infectivity 
of BTV in insects, likely by cleaving VP2 from the virion to generate virus 
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subparticles that have been shown to be up to ten times more infectious to 
Culicoides-derived, but not mammalian, cells (Darpel et al., 2011). The 
importance of these infectious virus subparticles in BTV transmission is 
unknown but they appear to facilitate virus entry into insect cells and may be 
linked to variations in the competencies of different Culicoides species 
(Mertens et al., 1996). 
 
Figure 2. BTV vector-borne transmission cycle (adapted from (Purse et al., 2005; Wilson et al., 
2009)). 
The virus replicates first in the midgut cells (day 0), then in the fat body 
cells (day 1) and neural tissues (day 3) (Fu et al., 1999). During these first 
three days following ingestion of the virus, an eclipse or partial eclipse phase 
occurs, such that either no BTV in the former case, or some BTV in the latter 
case, are detectable within the insect vector (Mellor et al., 2009). It is thought 
that this phase occurs because the virus is being inactivated in the insect's gut 
lumen, or perhaps due to viral excretion from the gut cells before proliferation 
is evident (Mellor et al., 2009). By day 5, BTV can be recognized in the 
salivary glands of the infected insect, where the virus replicates to 
approximately 1000 to 10000 times its day 0 titers and plateaus at these levels 
for the remainder of the insect's life (Foster & Jones, 1979). Researchers have 
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speculated that these final BTV titers may be limited by either the number of 
susceptible cells within a midge, or by a virus-vector balance that modulates 
the negative impact of virus replication on the vector (Mellor et al., 2009). The 
lifespan of a Culicoides midge is generally only 20 days but under consistently 
mild ambient conditions, it can approach 90 days in the field (Mellor et al., 
2000) or laboratory (Goffredo et al., 2004). 
Following the first infectious bite from a female Culicoides midge, BTV 
transmission from ruminant host to vector is possible beginning between one 
and two weeks (Figure 2). Since females feed multiple times over their lifespan 
at three-to-four-day intervals, virus transmission may occur already at the third 
feeding (Mehlhorn et al., 2007). It has been shown under both field and 
laboratory conditions that different midge populations demonstrate varying 
susceptibilities to different BTV serotypes, as well as to the same BTV 
serotype (Jones & Foster, 1978; Jennings & Mellor, 1987), at least partly due 
to species-specific saliva proteins. Furthermore, ambient temperature has also 
been shown to play a role in transmission, with transmission likelihood based 
on the balance between high temperatures that decrease vector lifespan but 
encourage an increase in vector bites, and conversely, low temperatures that 
increase vector lifespan yet result in a decrease of viral replication (Mellor et 
al., 2009). For example, a study of experimental infection of competent South 
African Culicoides species demonstrated that in C. bolitinos held at 25°C and 
15°C, titers of BTV-1 reached transmission potential (defined as ≥3 log10 
TCID50 per midge) two and eight days following infection, respectively, while 
in C. imicola held at 30°C and 23.5°C, BTV-1 titers reached this transmission 
potential four and ten days following experimental infection (Paweska et al., 
2002). At temperatures under 10-15°C, BTV replication is considered to cease 
entirely (Mullens et al., 1995; Paweska et al., 2002; Carpenter et al., 2011), but 
like African horse sickness virus, appears to persist for at least three weeks in 
surviving infected insects and can resume replication with warmer 
temperatures (Mullens et al., 1995; Wellby et al., 1996). 
Vertical transmission 
Although vector-borne transmission is the most common mode of BTV 
spread, cases of transplacental transmission following infection of pregnant 
sheep and cattle with certain BTV serotypes or strains have been reported 
(Luedke et al., 1977a; Wouda et al., 2008; Saegerman et al., 2011). 
Transplacental transmission was first documented in vaccine or laboratory 
strains, including BTV-1, -2, -4, -11, and -23, that had passage histories 
including chicken egg or cell lines (EFSA Panel on Animal Health and Welfare 
(AHAW), 2011; Rasmussen et al., 2013). The BTV-8 strain which circulated 
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in Europe from 2006 is the only field strain to date that has been shown to be 
transplacentally transmissible (De Clercq et al., 2008; Desmecht et al., 2008; 
Saegerman et al., 2011). BTV-8 RNA has additionally been detected up to ten 
days after birth in three calves (threshold cycle (Ct) 22, 27, and 27) that were 
born to two seropositive, but negative by reverse transcription-polymerase 
chain reaction (RT-PCR), heifers (Menzies et al., 2008). Virus was also 
isolated from the calf with the lowest Ct (22). Furthermore, BTV has been 
isolated from two newborn calves following natural transplacental transmission 
(De Clercq et al., 2008). While the duration of viremia in calves is unknown, 
there are indications that they are able to clear the virus and are not persistently 
infected (Maclachlan & Osburn, 2008). 
In addition to viral strain, stage of gestation also likely plays a role in the 
transplacental transmission of BTV (Flanagan & Johnson, 1995; EFSA Panel 
on Animal Health and Welfare (AHAW), 2011; Rasmussen et al., 2013). In 
particular, infection or vaccination of pregnant dams or ewes at early but not 
late gestation increases the risk of abortions or birth of abnormal or weak 
calves and lambs (Osburn, 1972; Thomas et al., 1986; Waldvogel et al., 1992b; 
Flanagan & Johnson, 1995). Moreover, as intramuscular inoculation of late-
term fetuses with a virulent BTV strain, but not an avirulent strain, can result in 
premature delivery or abortion of weak calves (Waldvogel et al., 1992a), it 
appears that BTV may not be able to cross the placental barrier during late 
gestation. 
Some studies have been performed to determine the potential of BTV 
transmission by artificial insemination or semen from naturally- or 
experimentally-infected rams or bulls, as reviewed in (Wrathall et al., 2006; 
EFSA Panel on Animal Health and Welfare (AHAW), 2011). As observed with 
transplacental transmission, some literature suggests that the probability of 
BTV excretion in semen may depend on whether the virus is a field or 
laboratory-adapted strain (Kirkland et al., 2004). Although there has been 
debate about whether the virus can be transmitted in this manner, there are 
nonetheless regulations impacting the transport of semen originating from 
animals in BTV zones. 
Potential direct transmission 
New evidence suggests that BTV-26, a serotype identified in Kuwait in 2010 
(Maan et al., 2011a), appears to be transmissible in goats by close, direct 
contact (Batten et al., 2014). There have also been reports of potential 
horizontal transmission of BTV-2 in sheep (Rasmussen et al., 2013) and of 
BTV-8 in cattle following contact with BTV-infected placentas (Menzies et al., 
2008) or after ingestion of BTV-spiked colostrum (Backx et al., 2009). Type 1 
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interferon (IFN) receptor-deficient (IFNAR(-/-)) mice, used as a mouse model 
for BTV infection (Calvo-Pinilla et al., 2009a), have also been shown to be 
orally susceptible to BTV-8 infection (Calvo-Pinilla et al., 2010). However, 
these mice are also susceptible to BTV infection by other routes of infection 
such as subcutanous (Jabbar et al., 2013) and intravenous routes (Calvo-Pinilla 
et al., 2009b; Mohd Jaafar et al., 2014). Since control measures are primarily 
based on vector-borne transmission of the virus, widespread direct 
transmission of specific BTV serotypes or strains could greatly impact virus 
spread as well as BTV research, diagnostic, and control strategies (Batten et 
al., 2014), and should be further explored. 
1.3.3 Geographical and seasonal distribution 
As shown in Figure 3, BTV has been identified on every continent except 
Antarctica, though the geographical distribution of BTV serotypes differs by 
region. Typically, clinical BT disease can occur year-round in tropical regions, 
where the virus is endemic, and seasonally (late summer and fall) in temperate 
regions (Gerry et al., 2001; Charron et al., 2011; Coetzee et al., 2012; Mayo et 
al., 2012).  
Figure 3. Global distribution of BTV serotypes (modified from (Wilson et al., 2009; Tabachnick, 
2010)). The recognized latitudinal range of BTV-competent Culicoides midges until 1998 is 
indicated by the orange band while the yellow band indicates the updated latitudinal range of 
competent vectors, following BTV-8 outbreaks in Europe. 
BTV in Europe 
Until recently, BTV was considered to be limited to the African continent and 
regarded as the cause of an exotic disease with some infrequent and short-lived 
incursions into European countries (Gibbs & Greiner, 1994). In 1998, BTV-9 
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was identified in Turkey, Bulgaria, and Greece, then spread to neighboring 
countries (including Italy) through 2001 (Zientara & Sánchez-Vizcaíno, 2013). 
BTV-1, -4, and -16 were also identified in southern Europe during that time, 
and in 2000, BTV-2 was detected in France and Spain (Saegerman et al., 
2008). These BTV serotypes continued to move westward and by 2005, the 
virus had been identified in over a dozen western and southern European 
countries and caused the death of over one million sheep (Saegerman et al., 
2008). In August 2006, a new outbreak of BTV occurred, this time due to 
serotype 8 and extending from central Europe (Luxembourg, northern France) 
to northern Europe (Belgium, Germany, and the Netherlands) (Saegerman et 
al., 2008). This northward expansion of BTV was likely at least partly due to 
the climate change-related expansion of its insect vector (Purse et al., 2005), 
but the exact mechanisms of the emergence of BTV-8 in northern Europe are 
unknown. The virus was eventually detected in southern Sweden in September 
2008 (Lewerin et al., 2010), and reached its northernmost-recorded latitude of 
53°N in Vest-Agder county, Norway, in February 2009 (ProMED-mail, 2009). 
Around the same time, vaccine strains of BTV-6 and -11 were also identified 
in a limited area in northern Europe, but did not reach the same latitude as 
BTV-8 (De Clercq et al., 2009; van Rijn et al., 2012). Concurrent with the 
BTV-8 outbreaks, an outbreak of BTV-1 in southern Europe, including Spain, 
Italy, and France, also occurred from 2007, and resulted in similar clinical 
disease in sheep, but not cattle (Allepuz et al., 2010). 
Since then and following vaccination campaigns, much of northern and 
central Europe have regained BTV-free status, but BTV restricted zones 
remain in Spain, Portugal, southern Italy (including Sardinia), Corsica, Malta, 
Cyprus and several Greek islands (Figure 4). The BTV-8 which was first 
identified in the northern European outbreak remains present in certain areas of 
southern Europe but appears to have disappeared entirely from northern 
European countries. 
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Figure 4. Bluetongue serotype distribution within the European Union in September 2007 (A) and 
June 2014 (B) (European Commission, 2014). 
Overwintering 
One mystery that remains to be solved regarding BTV is its apparent ability to 
"overwinter," or to survive during cold seasons in temperate regions where 
there is ostensibly no contact between the vector and its host. As reviewed by 
Wilson (Wilson et al., 2008), three general principles suggest possible 
explanations for this phenomenon of BTV: i) the virus is able to persist in the 
vector; ii) the virus is able to persist in the host; or iii) the virus is able to 
persist in different vectors or hosts as yet undetermined. 
If BTV is able to persist in the Culicoides vector, it should be able to be 
identified in either the adult (indicative of persistent infection) or larval stage 
(indicative of transovarial passage). Most Culicoides survive cold winter 
months as larvae (Kettle, 1962), but full BTV RNA has rarely been detected in 
the larval or pupal stage of midges and the virus has not been isolated from any 
of these samples (Mellor, 1990; White et al., 2005). However, this potential 
mechanism of overwintering remains to be further evaluated. It is possible that 
under mild winter conditions or by moving indoors (European Food Safety 
Authority; Losson et al., 2007; Lysyk & Danyk, 2007), some adult midges may 
also be able to survive beyond their usual 20-day lifespan. Although 
theoretically possible over mild winters, it seems unlikely that adult Culicoides 
are able to survive the three-to-nine months required for overwintering. 
Alternatively, if BTV is able to overwinter in ruminant populations, it must 
accomplish this either through persistent infection where no detectable virus is 
present, through vertical (transplacental) transmission, or through horizontal 
(sexual) transmission. Non-infectious BTV RNA has been detected in blood 
several months after infection in cattle (Katz et al., 1994), and some studies 
have been suggestive of persistent experimental BTV infection of cattle and 
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sheep (Luedke et al., 1977b; Takamatsu et al., 2003). However, these studies 
have not been repeated under natural conditions. Transplacental transmission 
has also been documented for certain BTV serotypes or strains (please refer to 
section 1.3.2) and there are indications that cows infected at an intermediate 
stage of gestation can give birth to viremic calves (Gibbs et al., 1979; De 
Clercq et al., 2008), which may potentially provide a mechanism for 
overwintering. On the other hand, it seems unlikely that horizontal (sexual) 
transmission would provide an overwintering opportunity, as trade regulations 
stipulate that semen must be tested for BTV before shipping and it is not 
certain that BTV can be transmitted horizontally (EFSA Panel on Animal 
Health and Welfare (AHAW), 2011). 
Finally, transmission via ticks or sheep keds may also provide opportunities 
for overwintering (Luedke et al., 1965; Stott et al., 1985b; Bouwknegt et al., 
2010), but the potential ability of these insects to transmit BTV has only been 
shown under experimental conditions. Other ruminant hosts that may go 
unnoticed if subclinically infected with BTV, such as wildlife, may also 
provide an opportunity for BTV overwintering and should be further 
investigated. 
1.4 Host-pathogen interactions 
1.4.1 Pathogenesis and innate immune response to BTV 
In typical cases, BTV enters the ruminant host through the bite of an infected 
Culicoides midge. This transmission is effective, as only 3 log10 TCID50 of 
virus is required per midge to infect a susceptible ruminant (Fu et al., 1999). 
Proteins present in the saliva of competent Culicoides may also play a role in 
BTV transmission, by recruiting inflammatory leukocytes, such as γδ T cells, 
in which the virus can replicate (Takamatsu et al., 2003; Darpel et al., 2011). 
BTV replicates in two phases called primary and secondary replication, 
respectively (Dal Pozzo et al., 2009). Its primary replication occurs over 
approximately two to three days in conventional dendritic cells at the 
inoculation site and in regional lymph nodes (Barratt-Boyes & MacLachlan, 
1994; Hemati et al., 2009). Subsequently, BTV-infected lymphocytes and 
monocytes, dendritic cells, and macrophages from the lymph nodes (Barratt-
Boyes & MacLachlan, 1994; MacLachlan et al., 2014) enter circulation and are 
carried to the spleen, lungs, liver, other lymph nodes, or other organs 
(MacLachlan et al., 1990) for secondary replication in mononuclear 
phagocytes and endothelial cells (Barratt-Boyes & MacLachlan, 1994; 
MacLachlan, 2004). Secondary replication occurs over the subsequent four to 
twenty days. During this time, BTV is physically associated with platelets, 
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mononuclear cells, and erythrocytes (MacLachlan et al., 1990). Depending on 
the species, age, and virus serotype, viral RNA can be detected by RT-PCR 
following secondary replication for up to 167 days or 222 days in sheep and 
cattle, respectively (Richards et al., 1988; Vögtlin et al., 2013). However, it is 
important to note that although BTV RNA can be detected in the blood of 
infected cattle for long periods of time, the infectious virus itself has only been 
isolated for 39-56 days (MacLachlan et al., 1994; Di Gialleonardo et al., 2011), 
and any PCR-detected BTV after this point has not been shown to be infectious 
in vivo (Katz et al., 1994). Furthermore, BTV's association with erythrocytes, 
which protects the virus from clearance by neutralizing antibodies, may explain 
its prolonged viremia (MacLachlan et al., 1990), but viruses cannot replicate in 
red blood cells due to their lack of cell machinery. Because BTV can be 
isolated from most blood cell fractions, with the highest viral titers detected in 
the most common cell types, its association with blood cells appears to be non-
specific (Barratt-Boyes & MacLachlan, 1995), and perhaps achieved through 
attachment to sialic acid (Zhang et al., 2010). 
Although the pathogenesis in sheep, cattle, and other ruminants is quite 
similar, there are clear differences in the pathogenicity and virulence of certain 
BTV strains in different ruminant species and breeds. These differences are 
largely attributed to species-specific variations in the susceptibility of 
endothelial cells (ECs) to BTV infection and to associated proinflammatory 
cytokine production (Coen et al., 1991). For example, it has been shown that 
ovine ECs more rapidly produced higher levels of proinflammatory cytokines 
than bovine ECs, despite lower levels of BTV replication (Russell et al., 1996; 
DeMaula et al., 2001, 2002a; b). In particular, the increased ratio of plasma 
thromboxane, a vasoconstrictor, to prostacyclin, a vasodilator, observed in 
sheep but not cattle may help explain the dissimilarities in BT disease among 
ruminant species, including hemorrhage and edema. Furthermore, BTV 
infection has been associated with the induction of type I IFNs (as reviewed by 
(MacLachlan et al., 2014; Vitour et al., 2014)), which are important for 
stimulating and shaping adaptive immune responses, and the absence of type I 
IFNs may impede the development of a protective immune response against 
BTV (Rodríguez-Calvo et al., 2014). NS3 in particular has been shown to 
interfere with the production of type I IFN (Chauveau et al., 2013) and 
therefore may play an important role in BTV pathogenesis. It has also been 
noted that the balance of early CD4+ and CD8+ lymphocyte proliferative 
responses differed between sheep and cattle following BTV infection, with a 
significant, and potentially protective, increase in both CD4+ and CD8+ T cell 
responses detected in infected cattle, but an increase in primarily CD4+ T cells 
in sheep (Ellis et al., 1990). 
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1.4.2 Protein-specific humoral immune responses 
As noted above, BTV infection is marked by species and breed differences in 
clinical signs and immune responses (Neitz, 1948; Berry et al., 1982). The 
main results concerning species-specific and protein-specific humoral immune 
responses to BTV have been summarized in Table 1 as well as in the following 
text. 
VP2 induces virus neutralizing antibody responses in mice and ruminants 
(Huismans & Erasmus, 1981; Inumaru & Roy, 1987; Roy et al., 1990). Since 
BTV serotype is defined using virus neutralization assays, it is also considered 
to be the serotype-determining protein (Huismans & Erasmus, 1981). These 
antibodies are detected approximately two weeks after natural infection and 
can persist for up to at least four to six years (Eschbaumer et al., 2012). 
Neutralizing antibody presence is highly linked with protection (Jeggo et al., 
1984b; Roy et al., 1990; Oura et al., 2009), but no precise minimum protective 
titer is defined, presumably because cell-mediated immune responses also play 
an important role. However, it has been indicated that BTV-8 neutralizing 
antibody titers of at least 1-1.5 log10 TCID50 may be required for long-term 
protection in lambs (Oura et al., 2010). In addition to VP2, it has been 
suggested that VP5 may play a role in inducing virus neutralizing antibodies, 
likely through support of VP2 conformation (Roy et al., 1990), and VP5 has 
additionally been shown to influence the specificity of neutralizing antibodies 
(Cowley & Gorman, 1989; Mertens et al., 1989; DeMaula et al., 2000). 
However, recent experiments based on virus neutralizing antibody assays using 
reassortants between BTV-1 and BTV-8 have suggested that VP2 alone is 
responsible for determining BTV serotype (Shaw et al., 2013) and for inducing 
neutralizing antibodies (Kochinger et al., 2014). Besides the outer capsid 
proteins, no other BTV proteins are thought to induce or influence virus 
neutralizing antibody production as defined by standard BTV neutralization 
assays (Huismans & Erasmus, 1981; Kahlon et al., 1983; Huismans et al., 
1987; Inumaru & Roy, 1987; Roy et al., 1990). 
Non-neutralizing antibodies against BTV are also induced by VP2, as well 
as by other VP and NS proteins. In particular, VP7 induces high titers of IgM 
antibodies in ruminants as soon as 7-10 days following BTV infection (Zhou et 
al., 2001; Bréard et al., 2011) or IgM and IgG antibodies 7-21 days after 
vaccination with live or inactivated vaccines (Monaco et al., 2004; Gethmann 
et al., 2009; Oura et al., 2009; Bréard et al., 2011; Modumo & Venter, 2012). 
The detection of VP7-specific antibodies quickly indicates BTV infection of 
any serotype and IgG antibodies directed against VP7 can be detected for up to 
10 or even 13 months following vaccination in some ruminants (Hultén et al., 
2013; Zanella et al., 2013a). As a result, VP7 is commonly used in diagnostic 
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assays (Zhou et al., 2001; Hamblin, 2004; Mecham & Wilson, 2004; Anthony 
et al., 2007). BTV antisera has also been shown to recognize VP3, the other 
protein of the BTV inner capsid (Inumaru et al., 1987), and like VP7, VP3 and 
the proteins of the transcription complex (VP1, VP4, VP6) have also been 
shown to be serologically reactive across BTV serotypes (Mertens et al., 
2009). 
Despite being largely associated with the induction of cellular immunity, 
NS1, NS2, and NS3 have also been shown to induce humoral immune 
responses following BTV infection. The roles of these antibodies in viral 
clearance or protection are not known. In the sera of lambs and calves collected 
after vaccination, NS2-specific antibodies were regularly detected in 
serological assays, while antibody production to NS1 was less consistently 
identified (Richards et al., 1988). Additionally, NS1- and NS2-specific 
antibodies have been detected following natural infection in sheep or rams 
(Adkison et al., 1987), and high titers of antibodies directed against NS1 and 
NS3 were also observed following BTV infection (Anderson et al., 1993; 
López et al., 2006; Barros et al., 2009). 
1.4.3 Protein-specific cellular immune responses 
Since the mid-1960s, it has been suggested that cell-mediated immunity may 
play an important role in protection against BTV infection (Jochim et al., 1965; 
Luedke & Jochim, 1968). However, it was not until the 1980s that the specific 
correlation between cellular immunity and BTV protection in sheep was more 
thoroughly examined (Jeggo & Wardley, 1982a; b; Jeggo et al., 1984a; Stott et 
al., 1985a). Identification of the specific viral proteins that induce these 
responses continues to be performed using samples primarily from mice or 
sheep (Table 1). Both VP and NS proteins have been shown to induce some 
level of T cell responses. In general, the NS proteins have predominantly been 
associated with cross-serotype cellular immune responses (Andrew et al., 
1995; Jones et al., 1996; Janardhana et al., 1999). The duration of cellular 
immune responses following BTV vaccination or infection is not yet known. 
The protein-specificity of T cell responses induced by BTV infection or 
vaccination in cattle are poorly characterized. However, VP2 and NS1 have 
been shown to be strong inducers of cytotoxic T cells in sheep, followed by 
VP5 and NS3 (Andrew et al., 1995). In the same study, VP7 did not induce 
cytotoxic T cells (CTLs), and those that were induced by NS1, but not VP2, 
were shown to be reactive across serotypes. Both NS1 and VP2 have been 
shown to induce cross-serotype and serotype-specific T cell responses, 
including helper T cells, in other studies (Takamatsu et al., 1990; Janardhana et 
al., 1999; Rojas et al., 2014). VP7 has also been shown to provide protection in 
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the absence of neutralizing antibodies, presumably through the induction of 
non-neutralizing serum antibodies or cell-mediated immune responses (Wade-
Evans et al., 1996). This has also been shown for VP7 in combination with 
VP3 (Roy et al., 1994; Stewart et al., 2012). Janardhana et al. observed that 
neither NS2 nor NS3 induced CTLs in sheep (Janardhana et al., 1999). This is 
in contrast to Andrew's study (Andrew et al., 1995) and an earlier study in 
mice, in which NS1, NS2, and NS3 induced the highest amount of CTL 
responses (Jones et al., 1996). In fact, vaccine studies in Balb/C and CBA/Ca 
mice have demonstrated that NS2 alone can provide partial protection against 
BTV infection by inducing CTL production (Jones et al., 1997). In all of these 
studies, the protein-specific T cell responses have been variable among 
individuals and may be MHC (major histocompatibility complex)-restricted 
(Jeggo et al., 1985; Takamatsu & Jeggo, 1989). MHC molecules present 
specific antigens for recognition by T cells and the genes that encode them are 
highly polymorphic in cattle (Amills et al., 1998; Ellis & Codner, 2012) and 
other species. MHC-restriction of BTV protein-specific T cell responses could 
potentially impact vaccination, particularly for vaccines with protection based 
on cellular immunity, by resulting in variable levels of protection due to MHC 
diversity. 
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Table 1. Selected reference list for protein-specific humoral and cellular immune responses induced by experimental or natural BTV vaccination or infection, 
excluding the results of this thesis work. Antibodies to VP2 (including virus-neutralizing antibodies) and VP7 have been reported in numerous studies, of which 
only a few references are provided here. Where no references are indicated, no relevant references exist (to the best of my knowledge). 
 Humoral immune responses Cellular immune responses 
 Mice/Rabbits Sheep Cattle Mice/Rabbits Sheep Cattle 
VP2 (Huismans et al., 1987; 
Inumaru & Roy, 1987; 
Franceschi et al., 2011; 
Calvo-Pinilla et al., 
2012) 
(Richards et al., 1988; 
Odeón et al., 1999; 
Oura et al., 2009) 
(Savini et al., 2004a; 
Eschbaumer et al., 
2009; Celma et al., 
2013) 
CD4+ (Franceschi et 
al., 2011) 
CTL (Jones et al., 
1996) 
CD4+ (T helper) 
(Takamatsu et al., 
1990) 
CTL (Andrew et al., 
1995; Janardhana et 
al., 1999) 
- 
VP5 (Huismans et al., 1987; 
Calvo-Pinilla et al., 
2009a) 
(Richards et al., 1988; 
Wang et al., 1995, 
2013; Odeón et al., 
1999) 
(Odeón et al., 1999) - CTL (Andrew et al., 
1995; Janardhana et 
al., 1999) 
- 
VP7 (Calvo-Pinilla et al., 
2009a) 
(Richards et al., 1988; 
Wade-Evans et al., 
1997; Odeón et al., 
1999; Perrin et al., 
2007) 
(Richards et al., 1988; 
Barros et al., 2009) 
CD4+ (Rojas et al., 
2011) 
CTL (CD8+) (Rojas et 
al., 2011) 
No CTL (Andrew et 
al., 1995) 
Possible (Wade-Evans 
et al., 1997) 
CTL (Janardhana et 
al., 1999) 
- 
NS1 (Calvo-Pinilla et al., 
2012) 
(Adkison et al., 1988; 
Richards et al., 1988; 
Anderson et al., 1993) 
(Richards et al., 1988) CD4+ (Rojas et al., 
2014) 
CTL (Jones et al., 
1996, 1997; Rojas et 
al., 2014) 
CD4+ (Rojas et al., 
2014) 
CTL (Andrew et al., 
1995; Janardhana et 
al., 1999) 
- 
NS2 (Mecham et al., 1986) (Adkison et al., 1988; 
Richards et al., 1988) 
(Richards et al., 1988) CTL (Jones et al., 
1996, 1997) 
No CTL (Andrew et 
al., 1995; Janardhana 
et al., 1999) 
- 
NS3 - (López et al., 2006; 
Perrin et al., 2007; 
Barros et al., 2009) 
(Barros et al., 2009) CTL (Jones et al., 
1996) 
CTL (Andrew et al., 
1995) 
No CTL (Janardhana et 
al., 1999) 
- 
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1.5 Clinical signs 
Although the virus can infect all ruminants, clinical signs caused by natural 
BTV infection are traditionally observed only in sheep. Breed, age, sex, prior 
exposure to the virus, and environmental conditions can affect the nature of 
clinical disease following natural infection, as can the BTV serotype or strain 
(Ward et al., 1994; MacLachlan et al., 2009). In experimental infections, the 
route employed for inoculation (Umeshappa et al., 2011) as well as the passage 
history of the virus stock (i.e. in cell culture or from infected ruminants) 
(Eschbaumer et al., 2010) are important to consider when making conclusions 
concerning BTV infection, since differences, for example in virulence, can 
confound comparisons among studies (Coetzee et al., 2014). In general, the 
clinical course of BTV infection occurs from two days to two weeks post-
infection (Moulton, 1961). 
1.5.1 Clinical signs in small ruminants 
Clinical signs of BTV infection in sheep can range from mild to severe, with 
up to 90-100% morbidity possible for naïve populations of susceptible breeds 
(Moulton, 1961), such as the Merino and Poll Dorset breeds. BT disease has 
been shown to vary among individuals within the same breed following both 
natural and experimental infection (Backx et al., 2007; Darpel et al., 2007; 
Elbers et al., 2008; MacLachlan et al., 2008; Worwa et al., 2010). However, 
clinical signs are generally characterized by hyperthermia, nasal secretions, 
edema of the lip, tongue, face, and lymph nodes, hyperemia or hemorrhage of 
the mouth and tongue, ulcers of the oral cavity (such as of the dental pads), and 
inflammation of the coronary bands combined with lameness or difficulty 
walking (Moulton, 1961; Erasmus, 1975a). In severe cases, cyanosis of the 
tongue can also occur, giving the disease its name.  
BTV-8 infection of sheep has not been markedly different compared to 
infection with other BTV serotypes. However, clinical signs have generally 
been severe in selected breeds of animals in northern Europe (Backx et al., 
2007; Moulin et al., 2012) and BTV-8 appears to have a high virulence 
irrespective of sheep breed (Worwa et al., 2010). 
BT disease has been observed in goats, but is less pronounced than the 
disease observed in sheep. Often, BTV infection in goats is marked by 
hyperthermia with or without slight hyperemia around the nose (Erasmus, 
1975a). Experimental infection of goats with BTV-8 in some cases, however, 
has resulted in more severe clinical signs including dysphagia (difficulty 
swallowing), diarrhea, and lameness (Backx et al., 2007). Furthermore, 
although no signs of BT disease were reported in goats infected with BTV-25, 
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stillborn or weak-born kids, possibly attributable to BTV infection, were 
observed in the field (Chaignat et al., 2009) and the virus RNA was shown to 
persist in blood for at least 19 months (Vögtlin et al., 2013). These results 
indicate that BTV might also be considered a pathogenic virus of goats, 
depending on the virus serotype, and like cattle, an important part of the picture 
for controlling BTV spread. 
1.5.2 Clinical signs in cattle 
In contrast with sheep, cattle are often not clinically affected by viral infection, 
yet demonstrate long viremia that peaks one to two weeks later, though at 
comparable titers, than the viremia observed in sheep (Richards et al., 1988; 
Darpel et al., 2007). Therefore, they act as amplifying hosts for BTV 
(MacLachlan et al., 1994). The outbreak of BTV-8 in central and northern 
Europe, however, was distinguished by the appearance of clinical signs in 
cattle (as reviewed by (Dal Pozzo et al., 2009)). Lesions of the nasal mucosa, 
nasal discharge, and conjunctivitis were observed first following natural 
infection, succeeded by lethargy, appetite loss, skin lesions, and a decrease in 
milk production (Zanella et al., 2013b). Elbers and colleagues determined that 
dairy and nursing cows, as opposed to beef cattle, were most likely to be 
clinically affected by BTV-8 infection in the Netherlands (Elbers et al., 2008). 
Importantly, BTV-8 infection in pregnant cows resulted in abortions, 
stillbirths, mummified or malformed fetuses, or newborn calves with 
developmental problems including abnormal posture, blindness, uncontrolled 
or circling gait, and other central nervous signs caused by hydroencephaly in 
so-called "dummy calves" (Wouda et al., 2008; Dal Pozzo et al., 2009; Worwa 
et al., 2010). 
1.5.3 Clinical signs in other ruminants 
Since wildlife can play a significant role in the amplification or spread of 
certain viruses, clinical BT disease in wild ruminants has been investigated by 
experimental infection in numerous species. 
BT disease similar to that reported in domestic sheep has been observed in 
mouflon (Ovis aries musimon) (Fernández-Pacheco et al., 2008) and desert 
bighorn sheep (Ovis canadensis) (Robinson et al., 1967) following natural 
infection, as well as in white-tailed deer (Odocoileus virginianus) following 
both experimental and natural infection (Falconi et al., 2011). Clinical BT 
disease following experimental infection of European red deer (Cervus 
elaphus), North American elk (Cervus elaphus canadensis), and African 
blesbok (Damaliscus pygargus) was subclinical or mild (transient 
hyperthermia, conjunctivitis) and similar to that observed in cattle (Murray & 
Trainer, 1970; López-Olvera et al., 2010; Falconi et al., 2011). 
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In addition to wildlife, South American camelids such as llamas (Lama 
glama) and alpacas (Lama pacos, Vicugna pacos) have also been shown to be 
serologically or virologically positive for BTV infection and in a few cases, 
appear to have died of acute BTV infection (Henrich et al., 2007; Meyer et al., 
2009; Ortega et al., 2010). However, they are not considered important in the 
epidemiology of the recent BTV outbreaks in central and northern Europe 
(Schulz et al., 2012). 
1.5.4 BTV infection in carnivores 
In line with evidence that BTV can be transmitted by direct contact of 
ruminants, some cases of BTV infection and clinical disease have been 
documented in Eurasian lynx (Lynx lynx) housed in a Belgian zoo (Jauniaux et 
al., 2008) and several different species of African carnivores, including lions 
(Panthera leo) and spotted hyenas (Crocuta crocuta), have tested seropositive 
for BTV infection (Alexander et al., 1994). All of these cases are thought to be 
caused by ingestion of infected ruminants or their organs, as has been similarly 
documented for African horse sickness virus (Van Rensberg et al., 1981). 
However, there are also reports of canine abortions following use of a BTV-11-
contaminated modified live virus vaccine administered during a late gestation 
period (Evermann et al., 1994). These cases of BTV infection of carnivores 
have reported clinical problems such as abortion, fatality, and other clinical 
signs such as anemia and lung congestion with edema. However, the 
importance of clinical BT disease of carnivores in the field (if present) is not 
well understood. 
1.6 Diagnosis 
Clinical diagnosis is considered to be crucial during BTV outbreaks, as it can 
provide an opportunity for control measures to be quickly implemented 
(Mertens et al., 2009). However, as detailed previously, it can be difficult to 
diagnose BTV infection in cattle or goats when the clinical signs are mild or 
even subclinical, or in any ruminant when the signs are unspecific. 
Furthermore, as a notifiable disease in many countries, an early and correct 
confirmation of a clinical BT suspicion by direct or indirect diagnostic tests is 
required. The identification of BTV RNA, isolation of BTV using eggs or cell 
culture, and the detection of BTV-specific antibodies, are common and key 
methods used to diagnose BTV infection. Depending on the method, BTV can 
also be identified at the serogroup or serotype level. 
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1.6.1 Virological diagnosis  
BTV can be isolated in embryonated chicken eggs (ECE) or directly in cell 
cultures from blood, semen, or tissue samples (Clavijo et al., 2000). An 
intravenous route of inoculation of ECE has been shown to be more rapid and 
effective than yolk sac inoculation for virus isolation (Goldsmit & Barzilai, 
1985). Additionally, insect-derived cells, such as Culicoides-derived (KC) 
cells, have been shown to be more sensitive to BTV infection than many 
mammalian cell lines but they do not exhibit CPE (Mertens et al., 1996). Virus 
neutralizing antibody tests are the most specific method for determining BTV 
serotype, but can take over a week to complete and rely on access to reference 
sera. 
The OIE officially recommends the detection of segment 5, encoding NS1, 
by RT-PCR for the diagnosis of BTV (OIE, 2009) and it has been shown that 
real time quantitative-PCR (RT-qPCR) assays designed to detect this genomic 
segment are able to identify at least 24 of the 26 known BTV serotypes when 
using blood from infected ruminants (Polci et al., 2007; Toussaint et al., 2007). 
These assays, as well as a protocol identifying segment 1 (VP1) (Shaw et al., 
2007; Toussaint et al., 2007), have been shown to enable BTV RNA detection 
in the blood of ruminants as early as two days post-infection (Batten et al., 
2008a). Several RT-PCR assays have also been developed to detect VP3 and 
results based on genetic sequences may indicate the virus's geographic origin 
(Gould & Pritchard, 1990; Harding et al., 1995; Pritchard et al., 1995). 
Recently, RT-qPCR assays detecting segment 2 (VP2) of all 26 BTV 
serotypes have been developed by Maan and colleagues to facilitate rapid 
serotype determination using field and reference strains (Maan et al., 2012). 
The use of such virological methods for identifying genotypes corresponding 
to BTV serotypes provides a faster alternative to traditional, time-consuming 
techniques for determining serotypes during BTV outbreaks, such as virus 
neutralizing tests. 
1.6.2 Serological diagnosis 
Classically, serum neutralizing antibody tests are the most specific method for 
identifying BTV-specific antibodies in serum samples. These tests rely on 
access to the reference strain of the specific BTV serotype concerned and can 
take over a week to complete. They are the gold standard for serological 
diagnosis. However, these tests are serotype-specific and may be difficult to 
perform on a large number of samples, such as when required for surveillance 
purposes. Therefore, enzyme-linked immunosorbent assays (ELISAs), which 
rely on the detection of BTV-specific antibodies in the sera of susceptible 
animals, are routinely used. ELISAs often take less than a day to complete and 
as they can detect specific IgM antibodies (Zhou et al., 2001), recent BTV 
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infection can be identified. The use of competitive (c) ELISAs can additionally 
allow sera from several species to be analyzed using the same kit. 
To minimize the number of ELISAs required to cover the 26 recognized 
BTV serotypes, detection of antibodies against proteins conserved among 
serotypes have been developed. VP7 has been selected since this protein 
induces a strong humoral immune response. ELISAs that detect IgM and/or 
IgG serum antibodies directed against VP7 have been shown to work well to 
identify BTV infection irrespective of serotype (Gumm & Newman, 1982; 
Zhou et al., 2001; Hamblin, 2004; Mecham & Wilson, 2004; Vandenbussche et 
al., 2008). Using a cELISA directed against VP7 of BTV is a prescribed test 
for international trade (OIE, 2009) and is widely used across Europe. Recently, 
the results of two inter-laboratory ring trials indicated that six different 
commercially-available cELISA kits targeting VP7 were able to detect, by 21 
days post-infection, all of the BTV serotypes circulating in Europe at the time 
(Batten et al., 2008a). 
In addition to VP7, NS1 and NS3 have also been targets for BTV ELISAs, 
since they are only produced during viral infection in cells and therefore may 
indicate BTV replication (Anderson et al., 1993; Barros et al., 2009). 
Generally, some of the conserved BTV proteins, including VP7 and the NS 
proteins, may also be suitable targets for differentiating infected from 
vaccinated animals (DIVA). However, at present no DIVA vaccines are 
available on the market (please see section 1.7.2). 
1.7 Prevention and control 
Traditional prevention and control measures for viral livestock diseases include 
the restriction of animal trade movements or quarantine of sick animals, 
optimization of zoosanitary and other biosecurity approaches, treatment when 
available, vaccination, and eradication or pre-emptive slaughter. A 
combination of these measures is employed for some viral infections of 
livestock, such as classical swine fever in pigs (Moennig, 2000). For BTV, 
there is no specific treatment, and different approaches may be taken 
depending on whether the disease is endemic or epidemic in a particular 
region. Regardless of the control measure, reliable diagnostic tests and 
understanding of the epidemiological situation are essential to allow decision-
making bodies to make informed choices (Wierup, 2012). 
1.7.1 Biosecurity and animal movement control measures 
In endemic areas such as South Africa, where non-indigenous or naïve sheep 
breeds can be severely afflicted, vaccination is considered to be the best 
method for preventing BT disease caused by viral spread (Dungu et al., 2004). 
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However, biosecurity measures targeting vectors or vector-access to 
susceptible animals may also be employed (Erasmus, 1975b; Coetzee et al., 
2012), as well as trade restrictions and control of animal movement. Since 
competent Culicoides species are ubiquitous and because there is little interest 
in vaccinating indigenous sheep breeds (Dungu et al., 2004), eradication seems 
unlikely in these areas. Additionally, many BTV serotypes co-circulate in 
South Africa (Niekerk et al., 2003). This makes vaccination of non-indigenous 
sheep breeds the most practical and effective control method but also requires 
the use of multivalent vaccines. 
In epidemic areas such as Europe, animal movement controls and trade 
restrictions are often the first line of defense. During the BTV outbreaks in 
2000, this began with the establishment of protection and surveillance zones (3 
and 10 km radii, respectively) surrounding infected farms and the pre-emptive 
slaughter of all susceptible animals on those farms (Caporale & Giovannini, 
2010). No animals in the protection zones were allowed to leave and 
vaccination was acceptable as a complementary control strategy in these zones 
only (European Council, 1992). When it quickly became apparent that these 
tactics were insufficient against vector-borne BTV, larger protection and 
surveillance zones were demarcated and extra surveillance measures, including 
regular veterinary visits to confirm BT disease, were added (European Council, 
2000). Widespread vaccination was implemented as a response to the 
outbreaks (Caporale & Giovannini, 2010) and was generally considered 
successful in preventing further BTV disease and spread (Zientara & Sánchez-
Vizcaíno, 2013). 
1.7.2 Vaccines 
Currently, there are two types of vaccines against BTV that are commercially 
available (Table 2): i) modified live virus vaccines, which are attenuated forms 
of BTV; and ii) inactivated vaccines, which are composed of whole killed BTV 
plus an adjuvant such as aluminum and/or saponins. Each vaccine type has 
advantages and disadvantages, as reviewed below, and therefore the 
development of novel BTV vaccines using new technologies is an expanding 
area of research. 
Modified live virus vaccines (MLVs) 
The first vaccines against BTV were MLVs, developed by Arnold Theiler and 
colleagues at Onderstepoort, South Africa, in the early twentieth century 
(Verwoerd, 2009). Today, there are MLVs targeting a large number of BTV 
serotypes. The vaccine most commonly used in South Africa consists of three 
formulations of five different BTV serotypes each, attenuated by passage in 
both ECE and baby hamster kidney (BHK-21) cell culture (Coetzee et al., 
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2012). This vaccine regimen has been designed to provide long-lived 
protection across all included serotypes with minimal immunologic 
interference among serotypes. 
During the recent BTV outbreaks in Europe, MLVs were the only available 
vaccines up till 2004 (Di Emidio et al., 2004) (Table 2). Monovalent MLVs 
targeting BTV-2 and BTV-16, as well as multivalent vaccines directed against 
BTV-2/-4, BTV-2/-9 and BTV-2/-4/-9, were employed in France (Corsica), 
Italy, Portugal, and Spain in the early 2000s, depending on the epidemiological 
situation of the target region (Savini et al., 2008). Safety concerns related to 
the use of specific MLVs including BTV-2 and/or BTV-16 were raised due to 
adverse reactions observed in some vaccinated ruminants in certain regions 
(Monaco et al., 2004; Ferrari et al., 2005; Veronesi et al., 2010). As a result, 
the use of monovalent BTV-16 was discontinued. As with natural infection, 
species differences in the clinical signs of sheep, goats, and cattle were 
observed following the use of these MLVs, with clinical signs more severe in 
sheep (as reviewed by (Savini et al., 2008)). 
MLVs can be produced and administered in a cost-effective manner and 
have several benefits associated with their use. For example, only one dose is 
required to induce virus neutralizing antibodies (Monaco et al., 2004), small 
amounts of attenuated virus are enough to stimulate a protective immune 
response (Modumo & Venter, 2012), and the addition of an adjuvant is not 
necessary. However, although MLVs continue to be used with success in BTV-
endemic areas such as South Africa (Dungu et al., 2004) and North America 
(The Center for Food Security and Public Health, 2014), they have generally 
been associated with drawbacks, such as clinical disease in some breeds 
(including teratogenic effects and abortion when used during early gestation 
(Waldvogel et al., 1992b)), reduced milk production, viremia, potential 
reversion to virulence, reassortment with field strains, as well as undesirable 
trade restrictions since their use cannot be differentiated from natural BTV 
infection (Monaco et al., 2004, 2006; Savini et al., 2004b; c; Ferrari et al., 
2005; Veronesi et al., 2005, 2010; Batten et al., 2008b). Therefore, due to 
safety concerns as well as to lack of a DIVA characteristic, MLVs are 
generally less favored within the European Union compared to inactivated 
vaccines, despite their recent success in controlling BTV-2 and BTV-9 
outbreaks in parts of southern Europe (Patta et al., 2004). 
Inactivated vaccines 
Classic inactivated vaccines are produced as killed whole virus, often using 
heat, ultraviolet radiation (UV), or chemical methods, including hydroxylamine 
and binary ethylenimine (Campbell, 1985; Di Emidio et al., 2004; 
Ramakrishnan et al., 2005, 2006; Savini et al., 2007; Umeshappa et al., 2010). 
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The first inactivated BTV vaccines became available in Europe in 2005, and 
targeted BTV-2 (Zientara et al., 2010). Today, there are inactivated mono- and 
multivalent vaccines against BTV-1, -4, -8 and -9 as well, as summarized in 
Table 2. Compared to MLVs, inactivated vaccines are widely considered to be 
safer because they are not associated with viremia and do not allow the 
reassortment between field and vaccine strains. However, they are more 
expensive to produce and may be more costly to administer as they require two 
immunizations rather than one in order to provide a comparable duration of 
immunity (Rogan & Babiuk, 2005). Additionally, inactivated vaccines need to 
be formulated with an adjuvant so as to induce sufficient immune responses 
(Singh & O’Hagan, 2003). Common adjuvants used in inactivated veterinary 
vaccines include aluminum hydroxide, saponins, and emulsions. Inactivated 
vaccines against BTV-8 have been evaluated in Europe under experimental and 
natural conditions regarding their safety and protective efficacy. In brief, after 
two immunizations, they have been shown to be safe and induce protective 
immunity against experimental clinical and virological BTV-8 infection in 
primarily sheep (Gethmann et al., 2009; Hamers et al., 2009a; Oura et al., 
2009; Bartram et al., 2011; Bréard et al., 2011; Moulin et al., 2012; Pérez de 
Diego et al., 2012) for at least one year (Hamers et al., 2009b). In particular, 
the immune responses induced by vaccination with commercially available 
inactivated vaccines includes neutralizing antibodies, serum antibodies, and 
CD8+ T cells (Umeshappa et al., 2010; Pérez de Diego et al., 2012). Some 
mild localized reactions have also been observed following their use (Hamers 
et al., 2009a; Vetvac, 2014). Revaccination with inactivated vaccines is 
recommended after one year by manufacturers (Vetvac, 2014).
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Table 2. List of commercially available BTV vaccines, as adapted from (The Center for Food Security and Public 
Health, 2014; Vetvac, 2014). 
Vaccine name Manufacturer Hosts Pathogens Adjuvants Countries of 
distribution 
Blue Tongue Virus 
Vaccine 
Veterinary 
Vaccines 
Production Centre 
(KARI, Kenya) 
Goat,    
sheep 
polyvalent BTV 
(attenuated) 
None Kenya 
Bluetongue Vaccine Onderstepoort 
Biological 
Products Ltd 
(South Africa) 
 
Goat,    
sheep 
polyvalent BTV 
(attenuated) 
None Namibia, 
South Africa 
Bluetongue Vaccine Colorado Serum 
Company (USA) 
Goat,    
sheep 
BTV-10 (attenuated) None USA, Canada 
Bluevac BTV1 CZ Veterinaria 
S.A. (Spain) 
Cattle,   
sheep 
BTV-1 (killed) Aluminum 
hydroxide, 
saponin 
Europe* 
Bluevac BTV4 BTV-4 (killed) 
Bluevac BTV8 BTV-8 (killed) 
Bluevac BTV1+4 BTV-1,-4 (killed) 
Bluevac BTV1+8 BTV-1,-8 (killed) 
BlueVac-10 PHL Associates 
Inc. (USA) 
 
Sheep 
 
BTV-10 (attenuated) None USA 
BlueVac-11 BTV-11 (attenuated) 
BlueVac-17 BTV-17 (attenuated) 
Bluvax Veterinary 
Vaccines 
Production Centre 
(KARI, Kenya) 
Sheep BTV None Kenya 
BLUVAX Kenya Veterinary 
Vaccines Institute 
(Kenya) 
Sheep BTV-1,-2,-3,-4,-8,-12,-
134 (attenuated in 
embryonated chicken 
eggs) 
None Kenya 
Bovilis BTV8 Merck Sharp & 
Dohme Ltd (MSD 
Animal Health, 
United Kingdom) 
 
Cattle,   
sheep 
BTV-8 (killed) Aluminum 
hydroxide, 
saponin 
Europe* 
BTVPUR AlSap 1 Merial (France) Cattle,  
sheep 
 
BTV-1 (killed) Aluminum 
hydroxide, 
saponin 
Europe* 
BTVPUR AlSap 8 BTV-8 (killed) 
BTVPUR AlSap 1+8 BTV-1,-8 (killed) 
BTVPUR AlSap 2+4 Sheep BTV-2,-4 (killed)   
Freeze dried 
monovalent 
Bluetongue vaccine 
Central Veterinary 
Control and 
Research Institute 
(Turkey) 
Sheep BTV-4 (live) None Turkey 
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Syvazul 1 Laboratorios 
SYVA S.A. 
(Spain) 
Cattle,   
sheep 
BTV-1 (killed) Oil Spain, United 
Kingdom Syvazul 1+8 BTV-1,-8 (killed) 
Syvazul 8 BTV-8 (killed) 
Syvazul-4 Sheep BTV-4 (killed) 
Zulvac 1 Ovis Zoetis/Pfizer 
(United Kingdom) 
Sheep BTV-1 (killed) Aluminum 
hydroxide, 
saponin 
 
United 
Kingdom 
 
Zulvac 1+8 Ovis BTV-1,-8 (killed) 
Zulvac 8 Ovis BTV-8 (killed) 
Zulvac 8 Bovis Cattle BTV-8 (killed) 
*Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, 
Italy, Latvia, Lithuania, Luxembourg, Malta, The Netherlands, Poland, Portugal, Romania, Slovak Republic, Slovenia, Spain, 
Sweden, United Kingdom 
New vaccine designs 
New vaccine designs rely on the same basic approach as classic vaccines: 
utilizing live antigens or killed antigens. As discussed, classic vaccines against 
BTV have the advantage of working well to prevent and control virus spread, 
and therefore novel vaccines must match their efficacy. Additionally, the 
design of new vaccines should aim to improve upon the disadvantages of 
classic vaccines by enabling DIVA and by potentially targeting multiple 
serotypes of BTV. Both of these aspects are especially important for central 
and northern Europe, where the virus is not endemic but where BTV outbreaks 
appear to pose a permanent threat. Many of the experimental vaccines targeting 
BTV have been listed in Table 3, and the general advantages and disadvantages 
of the different approaches are addressed below. 
Recombinant viral vector vaccines consist of a live attenuated virus that has 
been genetically modified to include genes encoding foreign antigens, so that 
those genes can be expressed within the host and subsequently induce 
protective immunity against the target virus. Often, these antigens are produced 
in high number in host cells and therefore can induce strong immune responses 
(Calvo-Pinilla et al., 2014). Antigen choice is especially important for inducing 
protective immunity, but other crucial considerations include recombinant 
vector stability, host range, expression and conformation of the foreign antigen, 
duration of immunity, cost of production, and safety (Yokoyama et al., 1997). 
Potential pre-existing immunity and the location of the primary immune 
response to the viral vector itself can hinder the development of a protective 
immune response (Saxena et al., 2013). Furthermore, since recombinant viral 
vectors are genetically modified, countries can be hesitant to implement their 
use. Capripox virus (Wade-Evans et al., 1996; Perrin et al., 2007), canarypox 
virus (Boone et al., 2007), bovine herpes virus type 4 (Franceschi et al., 2011), 
and vaccinia virus (Lobato et al., 1997) vectors, among others, have all been 
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used with varying levels of success as the basis of recombinant viral vector 
vaccines against BTV (Table 3). 
Additionally, disabled infectious single cycle (DISC) vaccines have been 
developed using reverse genetics technology, such that one essential gene 
product is missing from the produced virion and therefore the vaccine virus is 
only able to replicate once in target cells. This type of vaccine may provide a 
safer alternative to MLVs, though more virus or several doses are likely needed 
for a DISC vaccine to be equally effective since the amplifying effect of MLVs 
is prevented under this design. Promising VP6-deficient DISC vaccines have 
been produced and shown to provide protection against experimental BTV 
challenge in sheep (Matsuo et al., 2011; Celma et al., 2013). 
Virus-like particle vaccines (VLPs) and subunit vaccines have also been 
shown to be promising vaccine candidates against BTV (Roy et al., 1994; 
Stewart et al., 2010, 2012). BTV VLPs are produced by infecting insect cells 
with recombinant baculoviruses that express genes encoding for VP2, VP5, 
VP3, and VP7, such that the produced proteins self-assemble into empty 
double-shelled particles (French et al., 1990). Due to their composition, VLPs 
are able to mimic the structure of native BTV and have been shown to 
effectively induce protective humoral immune responses (Stewart et al., 2010, 
2012). Like inactivated vaccines, which also consist of killed antigen, these 
vaccines require the use of an adjuvant in order to stimulate a sufficient 
immune response. Adjuvants provide the advantage of allowing potent immune 
responses to be quickly induced and can help to direct an immune response to 
be primarily humoral, cellular, or a combination of both (Petrovsky & Aguilar, 
2004). Antigen choice, which is possible in subunit vaccine development, can 
also facilitate the induction and direction of immune responses to optimize a 
vaccine's protective efficacy, provided sufficient information is available to 
allow informed choices. 
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Table 3. Selected reference list for recent experimental BTV vaccines, including expression system, 
BTV proteins included in vaccine formulations, target species, and resulting clinical and virological 
protection against BTV challenge of different severity. 
Reference Expression 
system 
Proteins 
(serotype) 
Species Clinical 
protection 
Virological 
protection 
Killed vaccines 
(Roy et al., 1990) Sf9-baculovirus VP2 (50 µg) 
(BTV-10) 
Sheep Partial Partial 
  VP2 (100, 200 
µg) (BTV-10) 
 Full Full 
  VP2, VP5 
(BTV-10) 
 Full  Full 
  VP1, VP2, 
VP5-7, NS1-3, 
(BTV-10); VP3 
(BTV-17) 
 Full  Full 
(Roy et al., 1994; 
Stewart et al., 
2012, p 2) 
 
Sf9-baculovirus Virus-like 
particles 
(VLPs): VP2, 
VP5, VP3, 
VP7 (BTV-1,  
-2, -8, -13, 17) 
Sheep Full  Full 
(Stewart et al., 
2012) 
 
Sf9-baculovirus Core-like 
particles 
(CLPs): 
VP3, VP7 
Sheep Partial  Partial 
(Jabbar et al., 
2013) 
Bacterial VP2, VP5, 
VP7 (BTV-8) 
IFNAR(-/-) 
mice 
Partial Partial 
(Mohd Jaafar et 
al., 2014) 
C41 (DE3) E. 
coli 
VP2, VP5 
(BTV-4) 
IFNAR(-/-) 
mice 
Full  Partial 
Live vaccines 
(Wade-Evans et 
al., 1996) 
Capripox virus VP7 (BTV-1) Lambs Partial Not tested 
(Lobato et al., 
1997) 
Vaccinia virus VP2 (BTV-1) Sheep Partial Partial 
VP2, VP5 
(BTV-1) 
Partial Full 
(Boone et al., 
2007) 
Canarypox virus VP2, VP5 
(BTV-17) 
Sheep Full Full 
(Perrin et al., 
2007) 
Capripox virus VP2, VP7, 
NS1, NS3 
(BTV-2) 
Sheep Partial Partial 
(Calvo-Pinilla et 
al., 2009b, 2012) 
Modified 
Vaccinia Ankara 
virus + DNA 
(BTV-4) IFNAR(-/-) 
mice 
Partial Full 
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*Bovine herpes virus type 4; **equine herpes virus type 1; ***disabled infectious single cycle 
 
DIVA 
DIVA is an increasingly important consideration for veterinary vaccine design 
because of the movement restrictions placed on BTV-positive ruminants during 
outbreaks (Bhanuprakash et al., 2009). Countries face losing their disease-free 
status following widespread vaccination using conventional vaccines, which 
can have a devastating economic effect and in some cases has driven countries 
to slaughter vaccinated animals that could not be differentiated from infected 
animals, as in the case of the 2001 outbreak of foot-and-mouth disease in the 
Netherlands (Pluimers, 2004; Meeusen et al., 2007). DIVA is also crucial for 
maintaining serological surveillance as a tool for monitoring changes in 
vaccine efficacy or local epidemiology, especially in regions with potential co-
circulation of several strains or serotypes (Uttenthal et al., 2009; Avellaneda et 
al., 2010). 
(Franceschi et al., 
2011) 
BoHV-4* VP2 (BTV-8) IFNAR(-/-) 
mice 
Partial Partial 
(Ma et al., 2012) EHV-1** VP2 (BTV-8) IFNAR(-/-) 
mice 
Partial None 
VP2, VP5 
(BTV-8) 
Partial Full 
(Kochinger et al., 
2014) 
Vesicular 
stomatitis virus 
(single-cycle) 
VP2 (BTV-8) Sheep Partial Partial 
 VP5 (BTV-8)  None None 
 VP2, VP5 
(BTV-8) 
 Full Full 
(van Gennip et al., 
2012) 
Reassortants 
(reverse 
genetics) 
BTV-6 
backbone + 
VP2, VP5 
BTV-1 
Sheep Partial Full 
 BTV-6 
backbone + 
VP2, VP5 
(BTV-8) 
Partial Full 
 BTV-6 Partial Full 
(Feenstra et al., 
2014) 
Reassortants 
with NS3/NS3A 
knockout 
mutation 
(reverse 
genetics) 
BTV-1 
backbone + 
VP2 (BTV-8) 
Sheep Partial Partial 
 BTV-6  
backbone + 
VP2 (BTV-8) 
Partial Full 
 BTV-8  Partial Partial 
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Currently, there are no commercially available DIVA-compliant BTV 
vaccines. Some studies have suggested that NS1 (Anderson et al., 1993) or 
NS3 (López et al., 2006; Barros et al., 2009) can be detected in infected, but 
not vaccinated, animals following the use of classic inactivated vaccines. 
However, since current vaccines contain whole virus and when inactivated may 
contain some of these NS proteins, there is a strong risk that false positives for 
infection, especially after repeated vaccination, can complicate their use as 
DIVA targets. This has been observed with foot-and-mouth disease (Paton & 
Taylor, 2011). Therefore, new strategies must be employed to create 
companion DIVA tests for existing vaccines, or to create effective next 
generation DIVA vaccines based on existing diagnostic tests. 
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2 Aims of the thesis 
The main aim of this research was to develop and evaluate a novel subunit 
DIVA vaccine against BTV-8 in cattle. The specific objectives were: 
 
Ø In study I, to formulate and optimize a novel subunit DIVA vaccine 
against BTV-8 by performing protein purification and stability analyses 
and by evaluating protein-specific immunogenicity in mice (Paper I) 
Ø In study II, to evaluate the safety and protein-specific immune responses 
induced by the experimental subunit vaccine in cattle, in comparison 
with a commercial inactivated vaccine against BTV-8 (Paper II) 
Ø In study III, to evaluate the protective efficacy induced by the 
experimental subunit vaccine in cattle, as well as the VP7-based DIVA 
aspect of the vaccine, following a virulent challenge with BTV-8 (Paper 
III) 
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3 Materials and methods 
This section provides descriptions of the materials and methods used in the 
three studies of this thesis work. Where methods are not described in detail in 
the publications, additional attention is provided here. 
3.1 Recombinant protein expression and production 
Two different expression systems were used to produce recombinant BTV 
proteins, by following the manufacturers’ protocols. For VP2 and VP5 of 
BTV-8 (French strain, isolated in 2006; molecular weight (MW): 111 and 59 
kDa, respectively) and NS1 and NS3 of BTV-2 (Corsican strain, isolated in 
2001; MW: 64 and 35 kDa, respectively), the respective protein-encoding 
genes were inserted into individual “bacmids” using recombination. Following 
individual infections of Spodoptera frugiperda (Sf9) cells, each recombinant 
protein was expressed in Bac-to-Bac® Baculovirus Expression Systems 
(Invitrogen, United Kingdom). For NS2 of BTV-2 (Corsican strain, isolated in 
2001; MW: 40 kDa), the protein-encoding gene was cloned into a pET28 
vector and expressed in BL21-AI™ Escherichia coli (Invitrogen, United 
Kingdom) (NS2; MW: 40 kDa), following the manufacturers’ protocols. All 
proteins were tagged with 6 Histidine (His) residues for later purification using 
nickel or cobalt affinity.  
Sf9 cells (Invitrogen, United Kingdom) were propagated in Sf-900™ III 
SFM medium (Invitrogen, United Kingdom) and on day of passage, infected 
with different recombinant baculoviruses expressing individual recombinant 
proteins VP2, VP5, NS1, or NS3. These infected Sf9 cells were harvested after 
48 to 96 h and then centrifuged for 10 min at 300 x g for storage as cell pellets. 
Recombinant NS2 expression was induced for 5 h in medium containing 
0.1% L-arabinose and 1 M IPTG, then centrifuged for 10 min at 500 x g for 
storage. All expressed proteins were aliquoted and stored at -80°C until 
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purified for use in purification and stability analyses or experimental 
immunizations and ex vivo immunological assays. 
3.2 Recombinant protein purification 
The purification method for individual recombinant BTV proteins was selected 
between His SpinTrap™ columns (GE Healthcare, United Kingdom) or 
HisPur™ Cobalt Spin Plates (Pierce, USA), and the corresponding 
manufacturers’ protocols were then specifically optimized per protein 
regarding the lysis and elution buffers, as described in Figure 5 (final buffers 
shown in Table 4). Briefly, purification results following differences in 
imidazole concentration, pH, salt concentration, addition of detergent, working 
temperature, freeze-thaw cycle, and use of NP-40 lysis buffer were compared 
to the purification results following the manufacturers’ protocols to determine 
an optimized lysis buffer per recombinant protein. Variations in imidazole 
concentration were tested to optimize protein-specific elution buffers in 
comparison with the manufacturers’ protocols. 
 
 
Figure 5. Optimization process of purification protocols for recombinant BTV proteins. Buffer 
variations were tried in sequence as indicated horizontally, until acceptable purity was achieved. 
In addition to using optimized buffers for each recombinant protein, the 
manufacturers' protocols were followed with two exceptions: (1) lysed sample 
that flowed through the columns or plate wells was reloaded onto the same 
column or plate well, and incubation and centrifugation was repeated before 
washing; and (2) the total volume of optimized elution buffer was divided into 
four parts and added separately per column or plate wells, with an incubation 
step of 5 min at +4°C and centrifugation at 100 x g for 1 min (columns) or 500 
x g for 3 min (plate wells) in between each addition. 
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             Table 4. Serotype, expression system, and optimized parameters for purification of His-tagged recombinant BTV proteins VP2, VP5, NS1, NS2, and NS3. 
 VP2 VP5 NS1 NS2 NS3 
Serotype BTV-8 
 
BTV-8 BTV-2 BTV-2 BTV-2 
Expression system Baculovirus/Sf9 cells 
 
Baculovirus/Sf9 cells Baculovirus/Sf9 cells BL21 E. coli Baculovirus/Sf9 cells 
Purification method 
(affinity) 
HisPur spin platesb                 
(cobalt) 
 
His SpinTrap columnsc      
(nickel) 
HisPur spin plates                  
(cobalt) 
HisPur spin plates                   
(cobalt) 
His SpinTrap columns 
(nickel) 
Lysis buffer 50 mM sodium 
phosphate, 300 mM 
sodium chloride, 5 mM 
imidazole 
Not applicable 1 mM MgCl2, 20 mM 
imidazole, Benzonase 
nuclease HCd, in PBS 
50 mM sodium 
phosphate, 300 mM 
sodium chloride, 5 mM 
imidazole, 100 µg/ml 
lysozymed 
 
NP-40 lysis buffere 
Elution buffera 50 mM sodium 
phosphate, 300 mM 
sodium chloride, 150 
mM imidazole 
Not applicable 500 mM imidazole in 
PBS 
50 mM sodium 
phosphate, 300 mM 
sodium chloride, 150 
mM imidazole 
50 mM sodium 
phosphate, 300 mM 
sodium chloride, 500 
mM imidazole 
                      aAll buffers contained EDTA-free complete protease inhibitor cocktail tablets (Roche Applied Sciences, United Kingdom) 
                      bPierce, USA 
                      cGE Healthcare, USA 
                     dSigma Aldrich, USA. HC, high concentration 
                     eNational Veterinary Institute (SVA), Sweden
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3.3 Recombinant protein identification and quantification 
The presence of each recombinant protein was determined by Coomassie 
staining of sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) gels and Western blot. All procedures were performed at room 
temperature unless otherwise indicated. 
For SDS-PAGE, protein samples were diluted in Laemmli buffer (Bio-Rad 
Laboratories, USA), heated at 96°C for 5 min, then run on a 4-15% SDS-
PAGE gel (Mini-PROTEAN® TGX™ precast gels, Bio-Rad, USA) at 200V 
for approximately 40 min. The gel was then washed in distilled deionized 
water (ddH2O) and fixed for 30 min in fixing solution containing 25% 
isopropanol, 10% acetic acid, and 65% ddH2O. Fixed gels were washed before 
incubating in Coomassie stain for 2 h, followed by de-staining in 10% acetic 
acid. 
For Western blot, the gel was transferred at 50V for 1 h to a nitrocellulose 
membrane, blocked in 2% (w/v) BSA in PBS for 1 h, and then washed 3 times 
5 min in PBS-Tween. Washed membranes were incubated in primary antibody 
for 2 h, washed again in PBS-Tween, and incubated in secondary antibody for 
1 h. After a final washing step, visualization was performed using Stable DAB 
(Invitrogen, United Kingdom).  
For mass spectrophotometry, selected protein bands for individual 
recombinant proteins were excised from Coomassie-stained SDS-PAGE gels 
and brought to SciLifeLab (Uppsala, Sweden) for identification. Proteins were 
in-gel digested using trypsin, then either individually resolved in 5 µl of 30% 
acetonitrile and 1% formic acid (VP2) or in 15 µl 0.1% formic acid (VP5, NS1, 
NS2, and NS3). Resolved VP2 was loaded onto an MTP 384 ground steel 
target using the dried droplet technique and an α-cyano-4-hydroxycinnamate 
matrix. Mass spectra were recorded in positive mode on an Ultraflex II 
MALDI TOF mass spectrophotometer (Bruker Daltonics, Germany) and then 
peptide mass mapping was performed in MASCOT (Mascot Science, United 
Kingdom). For resolved VP5, NS1, NS2, and NS3, peptides from individual 
recombinant proteins were separated using a reversed-phase C18-column and 
electrosprayed on-line to an LTQ Orbitrap Velos Pro ETD mass 
spectrophotometer (Thermo Finnigan, Germany). Collision-induced 
dissociation (CID) was applied to perform tandem mass spectrophotometry 
before using MASCOT to perform database searches against proteins in the 
NCBI Virus database 
(www.ncbi.nlm.nih.gov/genomes/VIRUSES/viruses.html). 
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Individual protein quantification was performed using a Bradford assay 
read at 595 nm. Briefly, purified recombinant protein or known quantities of 
bovine serum albumin (BSA) were diluted 1:50 in Bradford solution 
(AppliChem, Germany) and incubated, protected from light, for 5 min prior to 
measurement of absorbance at 595 nm. Protein concentrations (µg/ml) were 
calculated based on the optical density (OD) values of the BSA standard curve. 
Digital analyses of protein band intensities were performed using the gel 
analysis method from the software program ImageJ (Schneider et al., 2012) for 
comparative analyses of protein purity percentages. 
3.4 Recombinant protein stability analyses 
Recombinant BTV proteins VP2, VP5, NS1, NS2, and NS3 were purified 
according to the corresponding manufacturers' protocols by nickel or cobalt 
affinity using His SpinTrap™ columns (VP5, NS3) or HisPur™ Cobalt Spin 
Plates (VP2, NS1, NS2), respectively. Aliquots from before and after 
purification (called "crude" and "semi-purified," respectively) were stored at 
+4°C and -80°C and tested for the presence of proteins after storage for 0 days, 
7 days (1 week), 14 days (2 weeks), and 35 days (5 weeks), as well as after 
storage for 616 days (88 weeks) at +4°C. Additional aliquots of VP2, NS1, 
NS2, and NS3 were prepared at different stages of optimized purification for 
experimental animal immunizations (purified, dialyzed, sterile-filtered VP2 
and NS2; purified NS1) and stored at -80°C for testing after 210 days (30 
weeks) and 560 days (80 weeks), respectively. Protein presence was 
determined by Western blot (as described in section 3.3). 
3.5 Animals, clinical examinations, and study designs 
Three different animal studies were performed throughout this thesis work and 
the vaccine design changed based on the results of these studies, as shown in 
Table 5. Clinical examinations, sampling, vaccinations, and viral challenge 
were performed in each study as indicated in Figure 6. 
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Table 5. Vaccines evaluated in each study. 
aIsconova AB, Sweden 
bMerial, France. Each dose contains ≥ 7.1 times the 50% cell culture infective dose (CCID50) of 
BTV-8 before inactivation (log10), plus aluminum hydroxide and saponin (adjuvants) 
3.5.1 Study I 
To evaluate specific immunogenicities of each protein using a minimum 
number of animals, 24 six to twelve-week-old female Balb/C mice were 
divided into four groups of six mice each and housed at the Animal House of 
the National Veterinary Institute (SVA, Uppsala, Sweden). All mice were 
subcutaneously immunized in the back of the neck at a four-week interval with 
homologous vaccines prepared from purified recombinant proteins VP2, NS1, 
NS2, and NS3 (with respective purities of 95%, 51%, 85%, and 77%) 
combined in 3 different formulations: i) 1.5 µg VP2 and 5 µg AbISCO-100 
(Isconova AB, Sweden) (name: vVP2); ii) 1.5 µg NS1, 1.5 µg NS2, 1.225 µg 
NS3, and 5 µg AbISCO-100 (name: vNS1/2/3); iii) 1.5 µg VP2, 1.5 µg NS1, 1.5 
µg NS2, 1.225 µg NS3, and 5 µg AbISCO-100 (name: vVP2NS1/2/3), per dose; 
or iv) 5 µg AbISCO-100 diluted in PBS (name: Control). Due to difficulties 
 Study I Study II Study III 
Species                
(age at start) 
Mice                         
(6-12 weeks) 
 
Cattle                        
(1.3-8.2 years) 
Calves                         
(0.6-1.1 years) 
Vaccine 
components/dose 
1.5 µg VP2 +              
5 µg AbISCO-100a 
150 µg VP2, 150 µg 
NS1, 150 µg NS2 +    
600 µg AbISCO-300 
 
150 µg VP2, 150 µg 
NS1, 150 µg NS2 +    
450 µg AbISCO-300  
 1.5 µg NS1, 1.5 µg 
NS2, 1.225 µg NS3 + 
5 µg AbISCO-100 
 
BTV Pur Alsap 8b 450 µg AbISCO-300     
in PBS 
 1.5 µg VP2, 1.5 µg 
NS1, 1.5 µg NS2, 
1.225 µg NS3 +          
5 µg AbISCO-100 
 
PBS  
 5 µg AbISCO-100 in 
PBS 
 
  
Vaccine regimen Subcutaneous 
immunizations on the 
back of the neck at a  
four-week interval 
Subcutaneous 
immunizations on the 
left side of the neck at a 
three-week interval 
Subcutaneous 
immunizations on the 
left side of the neck at a 
three-week interval 
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producing sufficient quantity of the purified protein, a lower amount of NS3 
was used per dose. Each dose of experimental vaccine formulation was 
adjusted to 200 µl with sterile PBS. 
Blood samples (approximately 50-100 µl) were collected from the tail of 
each mouse for protein-specific ELISAs before first immunization (week 0), 
before second immunization (week 4), and directly prior to euthanization by 
cervical spine dislocation (week 6). Following euthanization, spleens from all 
mice were surgically removed for immediate mononuclear cell isolation and 
subsequent lymphocyte proliferation assays. The Ethics Committee of Uppsala, 
Sweden approved this experiment (C237/10). 
3.5.2 Study II 
To test host-specific immunogenicity and safety of the experimental vaccine in 
cattle, fifteen healthy, bovine viral diarrhea virus-free, non-lactating Swedish 
red-and-white breed cows from a BTV-free region (range: 1.3-8.2 years of age; 
mean 4.3 years of age) were housed in the animal facilities of the Department 
of Clinical Sciences of the Swedish University of Agricultural Sciences (SLU, 
Uppsala, Sweden). The cows had not been previously vaccinated against BTV. 
All animals were divided into three groups of five cows each and immunized 
subcutaneously on the left side of the neck at a three-week interval with either: 
i) 150 µg each of purified VP2, NS1, and NS2, and 600 µg AbIsco®-300 
(Isconova AB, Sweden), adjusted to 2 ml per dose with sterile PBS (name: 
SubV); ii) 1 ml dose of commercial inactivated vaccine BTV Pur Alsap 8 (lot 
L372815; Merial, France), which according to the manufacturer contains 7.1 
times the 50% cell culture infective dose (CCID50) of BTV-8 before 
inactivation (log10) plus aluminum hydroxide and saponin as adjuvant (name: 
CV); or iii) 2 ml of sterile PBS (name: Control).  
A BD Vacutainer system (BD Biosciences, USA) was used to collect blood 
samples (approximately 25 ml) from all animals in dry and heparinized tubes 
for antibody and T cell proliferation analyses, respectively. Samples were 
collected at 0, 3, 6, and 9 weeks following first immunization.  
To monitor general and local adverse clinical reactions, clinical 
examinations including rectal temperature recordings were performed daily 
one day before to three days after each vaccination. Local swelling of injection 
sites were categorized by size and thickness as none, mild (<3 by 3 cm; flat), 
moderate (<10 by 10 cm; flat or diffuse), or severe (>10 by 10 cm; raised). The 
Ethics Committee of Uppsala, Sweden approved this experiment (C153/11). 
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3.5.3 Study III 
To test protective efficacy of the experimental vaccine against BTV-8 
infection, twelve healthy, conventionally-reared Holstein calves (range: 0.6-1.1 
years of age; mean: 0.8 years of age) that had not been previously vaccinated 
or infected with BTV, were housed at the Biosecurity Level 3 animal facilities 
of the National Institute of Agricultural Research (INRA) Research Center 
(Nouzilly, France). All animals were divided into two groups of six calves each 
and immunized subcutaneously on the left side of the neck at a three-week 
interval with SubV, composed of the same amount of recombinant proteins 
VP2, NS1, and NS2 as study II (150 µg) but with a reduced amount of 
AbIsco®-300 (450 µg), or with 450 µg AbIsco®-300 in PBS (group name: 
Control). Three weeks after second vaccination, all animals were 
subcutaneously inoculated simultaneously with 2.5 ml each of two BTV-8 viral 
suspensions isolated from a BTV-8-viremic cow. The first viral suspension was 
isolated on ECE and passaged twice on BHK-21 cells (BHK suspension; 6x106 
TCID50/ml) and inoculated on the right side of the neck, while the second viral 
suspension was isolated on KC cells and passed once more on the same cell 
line for virus amplication (KC suspension) and inoculated on the left side of 
the neck. Since no cytopathic effects (CPE) were observed following infection 
of KC cells, an RT-qPCR (Adiavet™ BTV Realtime ADI352, Adiagene, 
France) was performed using 10 µl of KC suspension and resulted in a Ct value 
of 14.1. Clinical examinations and collection of blood samples in ethylene 
diamintetraacetic acid (EDTA), dry, and heparinized tubes for analysis of 
viremia, humoral immune responses, and cellular immune responses, 
respectively, were performed as indicated in Figure 6.  
Clinical examinations were performed after each vaccination, including 
recording rectal temperatures and any localized swelling at the injection site. 
Localized swellings were considered none (no swelling), mild (<3 cm), 
moderate (>3 cm and <10 cm), or severe (>10 cm). For clinical examinations 
performed after BTV-8 challenge, clinical scoring was performed as described 
previously (Perrin et al., 2007), with minor modifications; respiratory signs 
were graded on a 3-point scale (serous, purulent, or necrotic nasal discharge) 
rather than a 2-point scale (mild or severe nasal discharge), and scores for 
rectal temperatures were included, as shown in Table 6. 
This study was approved by the local ethical review board of Val de Loire 
(CEEA VdL, committee number n°19, file number 2012-08-01). 
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Figure 6. Timeline of study I (A), study II (B), and study III (C). 
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Table 6. Clinical scoring for BTV-8 challenge, modified from (Perrin et al., 2007). 
 Score 
General State  
Good (normal behavior) 0 
Apathy (separation from the group, slow) 1 
Depression (lying down alone, still aware) 2 
Prostration (recumbent, no movement) 3 
Local Signs (edema or congestion)  
Face 1 
Nose 1 
Intermandibular space 1 
Lips 1 
Tongue 1 
Skin or hooves 4 
Right lymph nodes  
         Normal (none) 0 
         Slightly swollen (< 3 cm) 1 
         Swollen (3-10 cm) 2 
         Very swollen (< 10 cm) 3 
Left lymph nodes  
         Normal (none) 0 
         Slightly swollen (< 3 cm) 1 
         Swollen (3-10 cm) 2 
         Very swollen (< 10 cm) 3 
Locomotive Signs  
Stiffness 2 
Lameness 2 
Respiratory Signs  
Normal nasal discharge 0 
Serous nasal discharge 1 
Purulent nasal discharge 2 
Necrotic nasal discharge 3 
Cough 1 
Other  
Diarrhea 1 
Conjunctivitis 1 
Ulcers 1 
Plaintive bleating 1 
Excessive salivation 1 
Rectal Temperature (°C)  
38.0°C < T < 39.4°C 0 
39.5°C < T < 40.0°C 1 
40.1°C < T < 41.0°C 2 
41.1°C < T < 42.0°C 3 
T > 42.0°C 4 
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3.6 Virus detection 
Virus detection by inoculation of ECE and RT-qPCR was performed on 
samples collected in study III as indicated in Figure 6. 
3.6.1 ECE inoculation 
Virus inocula were prepared by diluting blood collected in EDTA tubes from 
all calves on PID8, 1:3 in PBS. A volume of 100 µl of diluted blood per calf 
(or of PBS for control eggs) was inoculated, in quintuplicate, in twelve-day-old 
embryonated specific pathogen free (SPF) chicken eggs (Håtunaholm, Sweden) 
by intravenous route, according to a general license for use of this technique 
(SVA, Sweden). All eggs were incubated at 37°C and monitored for seven 
days post-inoculation. Dead embryos were scored as positive if they showed 
hemorrhage characteristic of BTV infection. At completion of the study, 
embryos were incubated for 4 h at +4°C, homogenized, and stored at -70°C, 
and swabs of the thawed homogenates were stored in approximately 800 µl 
Tris-EDTA (TE) buffer before viral RNA extraction. 
3.6.2 RT-qPCR 
Viral RNA was extracted from whole blood samples and swabbed embyro 
homogenates using a Magnatrix robot at SVA (Uppsala, Sweden) and then 
incubated for 5 min at 95°C, to denature dsRNA to ssRNA. A pan-BTV RT-
qPCR based on segment 1 (VP1) of BTV (Toussaint et al., 2007) was 
performed on all extracted and denatured samples using 2 µl denatured RNA 
with 13 µl PCR mix from the AgPath-ID one-step RT-PCR kit (Ambion, 
USA). 
3.7 Humoral immunity analyses 
Analysis of humoral immunity induced by vaccination and/or viral challenge, 
including BTV-8 neutralizing antibody assays and protein-specific ELISAs 
against the purified recombinant BTV proteins, were performed in each study 
on serum samples collected as indicated in Figure 6. 
3.7.1 Virus neutralizing antibody assay 
Cattle sera were analyzed for the presence of specific BTV-8 neutralizing 
antibodies by classic virus neutralizing antibody tests in studies II and III.  
Vero cells in 100 µl minimal essential medium (MEM, Gibco, United 
Kingdom) supplemented with 1% minimal essential amino acids (Gibco) and 
1% HEPES (Gibco), were added per well to 96-well microtiter plates. Sera 
were heated for 30 min at 56°C and added in duplicate to wells at a range of 
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dilutions from 1:4 to 1:512 (study II) or 1:2 to 1:256 (study III). Virus was 
diluted in 50 µl and added to the plates. Plates were incubated for six (study II) 
or five days (study III) at 37°C and 5% CO2, then examined for the presence of 
virus-specific CPE. In both studies, the neutralizing titer was defined as the 
highest dilution in which the cell monolayer was intact. 
3.7.2 Detection of BTV-8 (VP2)-specific antibodies 
Specific antibodies to VP2 of BTV-8 were analyzed using an indirect ELISA 
and Western blot (study I), or a cELISA (ID Screen bluetongue serotype 8 
competition, ID VET, France) (studies II, III) according to the manufacturer's 
protocol. For studies II and III, detection of BTV-8 VP2-specific antibodies 
was also evaluated as an indicator of serotype-specific vaccination or infection 
as part of the DIVA analysis. 
For study I, VP2 and background control proteins (lysate from SF9 cells) 
were coated onto 96-well ELISA plates (Maxisorp, Nunc, Denmark) and 
incubated at +4°C for 16 h before 3 h blocking in 2% (wt/vol) BSA in PBS at 
room temperature. Plates were washed three times with PBS and then sera 
samples, which had been diluted in background control protein for 1 h, were 
added to wells for 1.5 h incubation at 37°C. Plates were washed three times 
with PBS-Tween, incubated at 37°C with rat anti-mouse IgG1 heavy chain-
HRP (MCA336P; AbDSerotec, United Kingdom) for 45 min, washed with 
PBS-Tween 3 times, and incubated with 3,3',5,5'-tetramethylbenxidine (TMB) 
substrate before addition of hydrogen peroxide stop solution. Corrected OD 
(COD = ODprotein-ODbackground) values were calculated from absorbance values 
measured at 450 nm. Titers were calculated by doing a linear regression to a 
cut-off based on the COD value of negative control sera at a dilution factor of 
50 and all data is presented as log10 values. For calculating means and 
performing statistical analyses, sera that were antibody-negative at the lowest 
tested dilution factor (50) were set to that threshold (dilution factor 50, i.e. 1.7 
log10 titer). 
Western blot, as described in section 3.3, was performed against VP2 and 
Sf9 cell lysate (background control), using cattle sera obtained three weeks 
after experimental infection with BTV-8, after two or eight immunizations with 
commercial inactivated vaccines against BTV-8, or from negative controls 
(non-infected and non-BTV-vaccinated animals). Diluted sera and sheep anti-
bovine IgG:HRP (AAI23P; AbDSerotec, United Kingdom) were used as the 
primary and secondary antibodies, respectively. 
For studies II and III, cELISAs were performed according to the 
manufacturer's protocol. The plates were read at 450 nm and validated 
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according to the manufacturer's specifications. All results are presented as 100 
minus percent competition ((ODsample/ODmean of negatives) x 100). 
3.7.3 Detection of BTV-2 NS1-, NS2-, and NS3-specific IgG1 antibodies 
Indirect ELISAs were used to detect NS1- and NS2-specific IgG1 serum 
antibodies (BTV-2) in all studies, and NS3-specific IgG1 serum antibodies 
(BTV-2) in study I only. Western blot was also performed in study I to detect 
bovine serum antibodies to NS1 and NS2. 
For study I, individual test protein or background control proteins (lysate 
from SF9 cells for NS1, NS3; lysate from BL21 E. coli for NS2) were coated at 
+4°C for 16 h onto 96-well ELISA microtiter plates (Maxisorp, Nunc, 
Denmark), blocked for 3 h in 2% (wt/vol) BSA in PBS at room temperature, 
and then plates were washed three times with PBS. Sera samples were diluted 
in corresponding background control protein and incubated for either 1 h (NS2) 
or 1.5 h (NS1, NS3), then added to the plates for 1.5 h incubation at 37°C. 
Plates were washed three times with PBS-Tween, incubated with rat anti-
mouse IgG1 heavy chain-HRP (MCA336P; AbDSerotec, United Kingdom) for 
45 min (NS1, NS3) or 1 h (NS2) at 37°C, again washed three times with PBS-
Tween, and then incubated with TMB substrate before adding hydrogen 
peroxide stop solution. COD values were calculated from absorbance values 
measured at 450 nm as described in section 3.7.2.  
For studies II and III, NS1- and NS2-specific indirect ELISAs were 
performed as for study I, with minor modifications: plates were blocked for 60 
min at room temperature, serum samples were incubated at 37°C for 75 min 
(NS2), and the secondary antibody used was HRP-conjugated mouse anti-
bovine IgG1 monoclonal antibodies (Svanova Biotech, Sweden) for 45 min 
incubation at 37°C. 
For studies I and III, antibody titers were calculated by doing a linear 
regression to a cut-off based on the COD value of negative control sera at a 
dilution factor of 50 (study I) and 10 (study III). For calculating means and 
performing statistical analyses, sera that were antibody-negative at the lowest 
tested dilution factor (50 or 10) were set to that threshold (dilution factor 50 or 
10). Results are presented as log10 values. 
For study II, COD values were calculated as described in section 3.7.2 and 
results are presented as percent positive ((ODsample/ODmean of positives) x 100). 
Western blot performed in study I, as described in section 3.3, was 
performed against NS1 and NS2 and relevant background controls (Sf9 cell 
and BL21 E. coli lysate, respectively), using serum samples described in 
section 3.7.2. 
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3.7.4 Detection of VP7-specific IgG or IgM antibodies for all BTV serotypes 
For studies II and III, the differentiation between infected and vaccinated 
animals was performed by detecting specific IgG or IgM antibodies directed 
against VP7 of any BTV serotype, using a double antigen sandwich ELISA kit 
(ID Screen® bluetongue early detection one-step, study II) or a cELISA kit (ID 
Screen® bluetongue competition, study III) according to the manufacturer's 
protocols (ID Vet, France). The plates were read at 450 nm and validated 
according to the manufacturer's specifications. Results are presented as 100 
minus percent competition (study II) or as percent competition (study III). 
3.8 Cellular immunity analyses 
Mononuclear cells from mouse spleens (study I) and peripheral blood 
mononuclear cells (PBMCs) from heparinized cattle blood samples (studies II, 
III) were isolated and restimulated ex vivo to evaluate protein-specific or virus-
specific cellular immunological responses. 
3.8.1 Lymphocyte proliferation analyses 
For study I, mouse spleens were removed directly after euthanization and 
flushed individually with sterile PBS to create single-cell suspensions. Samples 
were centrifuged over Ficoll-Paque Plus™ medium (GE Healthcare, United 
Kingdom) at 1300 x g for 15 min at +4°C and the lymphocytes were removed 
and washed twice in PBS by centrifugation at +20°C, first at 500 x g for 10 
min and then at 200 x g for 10 min.  
After the second wash, lymphocytes were counted using Türks solution, and 
diluted to 2x106 cells/ml (2x105 cells/µl) in RPMI medium supplemented with 
10% fetal calf serum. Cells were plated at a final concentration of 2x106 
cells/ml onto sterile 96-well round-bottomed plates in a volume of 100 µl/well.  
Isolated cells were restimulated, in quadruplicates, with individual proteins 
and relevant background controls at 0.03 µg/well then incubated for five days 
at 37°C and 5% CO2. Eighteen hours prior to measurement of absorbance by 
spectrophotometry at 570 nm and 595 nm, 20 µl of alamarBlue® reagent 
(Invitrogen, United Kingdom) was added to each well. OD values at 595 nm 
were subtracted from OD values at 570 nm per well, and COD values were 
calculated among the different groups for BTV protein-specific stimulations. 
For study II, PBMCs were obtained from heparinized blood samples from 
all cattle, as previously described (Taylor et al., 1995). In short, heparinized 
blood samples were diluted 1:1 in room-temperature PBS and added to Ficoll-
Paque Plus™ medium. Samples were centrifuged at 1100 x g for 30 min at 
+20°C and the lymphocytes were removed, washed, and restimulated as 
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described for study I (shown above). Restimulations were performed with 
0.03-0.18 µg/well of individual test proteins and relevant background controls. 
For study III, PBMCs were isolated from heparinized blood samples 
collected before challenge (6 weeks) and one week after challenge, as 
described for study II, then resuspended in bovine viral diarrhea virus-free fetal 
calf serum with 10% DMSO (Research Organics, USA) and frozen at -80°C 
for transport to Sweden. Cells were then stored in liquid nitrogen before 
analysis at 2x106 cells/ml for stimulations. Stimulations were performed, in 
duplicates, with 0.3-1 µg/well of individual proteins and relevant background 
controls as well as 103.5 TCID50/ml of UV-inactivated BTV-8 (equivalent Vero 
cells as background control). AlamarBlue® reagent was added 7-16 h prior to 
measurement of absorbance by spectrophotometry at 570 nm and 595 nm and 
COD values were calculated as described above. 
3.8.2 Detection of IFN gamma (IFN-γ) production of restimulated lymphocytes 
In study II, the presence of IFN-γ in the supernatants of restimulated 
lymphocytes (described in section 3.8.1) was quantified using a sandwich 
ELISA kit (ID Screen® ruminant interferon gamma kit) according to the 
manufacturer's protocols (ID Vet, France). The plates were read at 450 nm and 
then validated by following the manufacturer's specifications. Results are 
expressed as COD values. 
3.9 Statistical analyses 
Due to the structure of the sample data, non-parametric Wilcoxon rank sum, 
Wilcoxon sign rank, and Kruskal-Wallis tests were used for analysis among 
two independent, two paired, or three independent immunized groups, 
respectively, in the statistical program R (R Development Core Team, 2012). 
Where relevant, Student's one-tailed t-tests were performed in Excel. Statistical 
significance of the tests was set to a p value of ≤0.05 (*) or ≤0.01 (**) unless 
otherwise specified and where applicable, values are provided as the indicated 
group mean plus-or-minus the standard deviation (mean±SD). 
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4 Results and discussion 
4.1 Formulation and optimization of a novel DIVA subunit 
vaccine against BTV-8 
To develop a novel vaccine against BTV that could be safe, potentially 
adaptable to different serotypes, and DIVA compliant, we chose to pursue a 
subunit vaccine design. The rationale behind the formulation of the 
experimental vaccine was to include a cocktail of BTV proteins that could 
induce both protective humoral and cellular immune responses in cattle. Based 
on available information, five proteins were selected, of which some could 
induce serotype-specific protection (VP2, VP5 of BTV-8) (Stewart et al., 2012; 
Mohd Jaafar et al., 2014) as well as potentially protect across multiple 
serotypes (NS1, NS2, and NS3 of BTV-2) (Calvo-Pinilla et al., 2012), since 
several BTV serotypes were co-circulating in Europe when the project was 
designed. 
4.1.1 Production, expression, and quantification of recombinant BTV proteins 
for subunit vaccine design 
Recombinant BTV proteins VP2, VP5, NS1, and NS3 were produced in Sf9 
cells using a baculovirus expression system, while recombinant BTV protein 
NS2 was produced in a BL21 E. coli expression system. Both of these systems 
have been successfully utilized previously for BTV recombinant protein 
production (Inumaru et al., 1987; Jones et al., 1997; Mecham & Wilson, 2004; 
López et al., 2006; Jabbar et al., 2013; Mohd Jaafar et al., 2014) as well as for 
the production of commercial recombinant vaccines, such as Flubok® 
(influenza vaccine), Cervarix® (human papillomavirus vaccine), and 
SparVax® (anthrax vaccine). Additionally, the five target proteins were 
already expressed in these systems and available through collaboration in our 
laboratories. Baculovirus and E. coli production systems are commercially 
available and affordable, plus have the potential to rapidly produce large 
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quantities of functional recombinant protein when scaled up from laboratory to 
industrial settings, as reviewed by (Brun et al., 2011). Baculovirus expression 
systems additionally allow post-translational modification of proteins, 
including glycosylation. Moreover, both systems do not require fetal calf 
serum and are therefore bio-safe in that aspect. However, no expression system 
is perfect and reported difficulties with the E. coli system include lack of post-
translational modifications, potential misfolding of proteins, and risk of 
lipopolysaccharide (LPS) contamination. Similarly, baculovirus systems may 
not facilitate appropriate "mammalized" glycosylation of expressed proteins 
for use in vaccines (Harrison & Jarvis, 2006) and can be time-consuming when 
cloning the target genes into transfer vectors for generation of recombinant 
baculoviruses (Jayaraj & Smooker, 2009). In this thesis work, however, it was 
possible to use these systems to produce sufficient quantities of recombinant 
protein for practical use in vaccines and immunogenicity analyses. Adaptation 
of these systems to novel technologies, such as the use of baculovirus and 
silkworm larvae instead of insect cells (Kost et al., 2005), or by utilizing other 
promising systems, such as yeast (Shin & Yoo, 2013) or plant-based 
(Guerrero-Andrade et al., 2006) expression systems, may further enable their 
use for the production of greater quantities of recombinant protein.  
In contrast to other BTV experimental vaccine studies that used cell lysate 
rather than purified protein (Roy et al., 1990), we aimed to purify the 
recombinant proteins to be able to better evaluate protein-specific 
immunogenicities. Additionally, clearly-defined antigens such as purified 
proteins may be safer by inducing fewer secondary effects and are therefore 
highly desirable for commercial vaccine development (Clair et al., 1999). 
Nickel and cobalt affinity systems are commonly used for purifying His-tagged 
proteins. Purification protocols, including lysis and elution buffers, were 
optimized for each of the five recombinant proteins by testing between the two 
affinity systems, in combination with modifying salt and pH concentrations, 
adding several detergents, and changing the temperature of lysis buffers. 
Differences in the optimized protocols were dependent on their degree of 
success for purifying each protein. Optimized protocols were identified for 
VP2, NS1, and NS2 in cobalt plates, for NS3 in nickel columns (although it 
remained difficult to purify in sufficient quantity), but not for VP5 in either 
system (Paper I). Recombinant baculovirus-expressed VP5 with a glutathione 
S-transferase (GST)-tag has previously been purified from detergent-soluble 
extracts of infected cells (Hassan et al., 2001), but the recombinant protein 
used in the present project could not be solubilized despite many changes to the 
lysis buffer. VP5 has a hydrophobic region (Hassan et al., 2001) that may 
hinder its solubility (Yasui et al., 2010) under the conditions presented here 
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and may explain why the His-tagged VP5 could not be sufficiently and 
reproducibly purified. Modifying the recombinant protein, for example by 
using another affinity tag or by expressing a truncated version of the protein, 
could have potentially improved the solubility of VP5 and enabled its 
purification. However, recent studies have suggested that VP5 may not be 
essential for induction of BTV protection (Shaw et al., 2012; Mohd Jaafar et 
al., 2014) and as a result, it was decided to not pursue further investigations 
into purifying VP5. 
The final buffer protocols used for purification are shown in Table 4 
(section 3.2). 
4.1.2 Stability of recombinant BTV proteins 
The stability of the five recombinant BTV proteins was evaluated at different 
time points for different stages of purification, to determine how long batches 
of each of the recombinant proteins could be stored to perform the different 
experiments in this project. First, the stability of all five proteins, stored as 
semi-purified proteins at -80°C and +4°C, was evaluated after 0, 1, 2, and 5 
weeks. With the exception of NS2 when stored at +4°C for 5 weeks, all 
proteins were detected by mouse anti-histidine tag Western blot at all measured 
time points and temperature conditions. Additionally, each protein did not 
appear to degrade, as determined by digital image analysis, throughout these 
five weeks. 
Next, the protein stability in both crude and semi-purified extracts was 
evaluated after storage at +4°C for 88 weeks (termination of the part of the 
experiment that analyzed these samples). Whereas all five proteins were 
detected in crude extracts, only semi-purified VP2, NS1, and NS2 were 
detected under these storage conditions. These results indicate that the purity 
level of the proteins may influence their stability. 
Since VP5 could not be purified and NS3 was difficult to purify in 
sufficient quantity, only purified VP2, NS1, and NS2 were evaluated after 30 
and 80 weeks (endpoints of the individual experiments analyzing these 
samples) storage at -80°C. Additionally, dialyzed and sterile-filtered VP2 and 
NS2, but not NS1, were evaluated following 30 weeks storage at -80°C. NS1 
could not be sterile-filtered due to protein loss during the process, likely 
because the protein bound to the membrane, and there was no dialyzed aliquot 
at this time point for evaluation. However, NS1 tested negative for bacterial 
contamination, which if present, would have otherwise been removed by the 
sterile filter. All proteins were detected using Western blot under these 
conditions and time points and each protein demonstrated similar integrity as 
that observed before storage. 
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Taken together, these results indicate that VP5 and NS3 can be stored long-
term as crude aliquots and that VP2, NS1, and NS2 can be stored long-term in 
crude, semi-purified, or purified aliquots. Importantly for subunit vaccine 
development (Clair et al., 1999), the results presented here suggest that VP2, 
NS1, and NS2 can be purified and stored with minimal degradation for at least 
1.5 years at +4°C and therefore are suitable for vaccine use regarding shelf life. 
It would be interesting to further evaluate whether these proteins can be stored 
at room temperature, and for how long, as well as whether they can be stored in 
lyophilized forms. The storage of purified recombinant proteins as lyophilized 
aliquots at room temperature has previously been demonstrated (Diminsky et 
al., 1999; Dutta et al., 2001; Smallshaw & Vitetta, 2010) and would be 
desirable for commercial vaccine production. 
4.1.3 Selection of BTV proteins based on their immunogenicity for inclusion in 
experimental subunit vaccine 
Initially five recombinant BTV proteins were selected for evaluation but as 
noted above, recombinant VP5 could not be sufficiently and reproducibly 
purified. Therefore only the remaining four recombinant BTV proteins (VP2, 
NS1, NS2, and NS3) were included in different experimental formulations 
tested in a minimum number of mice, by following the three Rs (replacement, 
refinement, reduction) principle (CODEX, 2013). The formulations consisted 
of different protein combinations, rather than each of the proteins individually, 
in order to evaluate the potential stimulatory or suppressive interactions among 
the proteins in a minimum number of mice. Additionally, the different 
formulations were administered in combination with an adjuvant. Subunit 
vaccine formulations require adjuvants so that sufficiently high levels of 
immune responses are induced following vaccination. Adjuvants provide the 
added advantage of potentially directing the immune response, particularly 
towards a cellular immune response (Vogel, 2000). Neutralizing antibodies 
have been demonstrated to be crucial for serotype-specific protection against 
BTV (Huismans et al., 1987; Roy et al., 1990), but the importance of T cell 
responses in providing BTV protection has also been indicated (Jeggo et al., 
1984a, 1985; Jones et al., 1997; Calvo-Pinilla et al., 2012; Rojas et al., 2014). 
Leading adjuvants such as ISCOM-matrices are understood to help stimulate 
CD8+ T cells in particular (Robson et al., 2003), as well as CD4+ T cells 
(Pedersen et al., 2012), and since we had expertise using these adjuvants within 
our group, the AbISCO product line (including AbISCO-100 for smaller 
animals such as mice; AbISCO-300 for larger animals such as cows) was 
selected for inclusion in the protein formulations. The individual 
immunogenicities of each protein in combination with the ISCOM-matrix 
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adjuvant was evaluated using protein-specific humoral and cellular immunity 
analyses. 
Of these four proteins, NS3 was the most difficult to purify in sufficient 
quantity, and was thus ultimately included in the different formulations in a 
slightly lower concentration than the other proteins (1.225 µg/dose compared 
to 1.5 µg/dose). Using assays that were limited by low quantities of purified 
protein, it was not possible to determine if NS3-specific humoral immune 
responses were induced in immunized mice, and cellular immune responses 
were not detected (data not shown), despite evidence from others that NS3 
induces both humoral (López et al., 2006; Perrin et al., 2007; Barros et al., 
2009) and cellular (Andrew et al., 1995; Jones et al., 1996) immunity. For 
these reasons, NS3 was excluded from further analyses and from the final 
vaccine formulation used in the cattle studies. 
For the remaining three proteins (VP2, NS1, and NS2), specific serum IgG1 
antibodies directed against VP2 and NS2, but not NS1, were detected by 
indirect ELISA in immunized mice. Although not statistically significant, NS2 
tended to induce stronger antibody response when formulated with the NS 
proteins alone, compared to the formulation that included VP2. These ELISA 
results were supported by complementary studies using Western blot analyses, 
in which serum IgG antibodies from cattle experimentally-infected or 
vaccinated against BTV-8 recognized purified recombinant VP2 and NS2. 
Consequently, an indication of the tertiary conformation of the individual 
proteins was obtained before proceeding to large animal experiments. The 
results indicated that VP2 and NS2 were correctly folded to be recognized by, 
and thus to detect, BTV-8 antibodies. 
Regarding cellular immune responses, significantly higher specific spleen 
lymphocyte proliferative responses to VP2, followed by NS1 and NS2, were 
detected in samples from immunized mice, compared to control mice (p≤0.05 
for all). These results support previously published conclusions about the 
protein-specificity of induced T cell responses in mice and sheep (Takamatsu 
et al., 1990; Andrew et al., 1995; Jones et al., 1996, 1997). Taken together 
with the humoral immune results, these results suggested that the recombinant 
VP2, NS1, and NS2, when administered in combination with an ISCOM-
matrix adjuvant, were immunogenic in mice and thereby potentially 
immunogenic in cattle. Therefore, these three proteins and the ISCOM-matrix 
adjuvant were included in the final formulation of the experimental subunit 
vaccine (called SubV). 
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4.1.4 Modulation of adjuvant composition of SubV for cattle 
In study II, one dose of SubV consisted of 600 µg of AbISCO-300 (suitable for 
larger animals such as cows) and 150 µg each of VP2, NS1, and NS2 (Table 
5), and was prepared just before administration by first mixing the proteins 
together and then adding the adjuvant. The final volume was adjusted to 2 ml 
by addition of PBS. Controls received 2 ml PBS alone. SubV induced 
increased rectal temperatures for 24 h following first vaccination (group 
means: 39.2±0.3°C and  38.0±0.4°C for SubV and Control groups, 
respectively), as well as mild-to-moderate injection site swellings. Higher 
rectal temperatures (group means: 40.0±0.8°C and 38.0±0.3°C for SubV and 
Control groups, respectively) and more pronounced injection site swellings 
were also observed following second vaccination with SubV in comparison to 
first vaccination (Paper II). However, localized swelling disappeared less than 
one week after vaccination and no change in behavior or reduction in appetite 
was observed in any animal throughout the study. Localized reactions with 
transient fever have also been reported following use of commercial BTV-8 
vaccines, including Bluevac BTV8 (CZ Veterinaria S.A, Spain), Bovilis BTV8 
(Merck/MSD Intervet, United Kingdom), and BTVPUR AlSap 8 (Merial, 
France) (Vetvac, 2014). 
Both VP2 and NS2 were sterile-filtered to reduce the risk of contaminants 
before inclusion in the vaccines, and NS1 was tested and found negative for the 
presence of bacteria. ISCOM-matrices have been proposed to affect immune 
processes by accelerating and improving antigen uptake and presentation by 
antigen-presenting cells as well by inducing inflammation, including relevant 
cytokine production (Morein & Bengtsson, 1999; Morein et al., 2004; Lövgren 
Bengtsson et al., 2011). The inflammatory properties of ISCOM-matrices, 
likely due largely to the saponins included in their formulation (Smith et al., 
1998), can lead to some general and local reactions by inducing hyperthermia 
and moderate localized swelling at the injection site, as has been observed in 
other studies (Heldens et al., 2009; Blodörn et al., 2014). Therefore, it was 
hypothesized that the clinical signs observed following vaccination in study II 
could have been caused by the high amount of adjuvant included in the 
vaccine. Furthermore, in contrast to the cows vaccinated in study II, younger 
and smaller calves were to be immunized with SubV in study III and the 
adjuvant composition of SubV needed to be modulated accordingly. The 
adjuvant amount was reduced from 600 µg/dose in study II to 450 µg/dose for 
study III, using the same quantity of proteins. Consequently, milder secondary 
reactions and no statistically significant temperature increase was observed 
following vaccination with SubV compared to controls receiving adjuvant 
alone (p=0.38) (Paper III). Less localized injection site swelling was observed 
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following first vaccination with SubV, and swelling abated more rapidly 
following second vaccination compared to earlier (Paper II, data not shown). 
Improvements in protein purity (data not shown) may have also contributed to 
decreased localized swelling following vaccination. Notably, the reduction of 
adjuvant quantity in SubV did not seem to affect the induction of immune 
responses by the vaccine, as described in the following sections. 
4.2 Humoral immune responses against BTV in cattle following 
vaccination and challenge 
4.2.1 Induction of BTV-8 neutralizing antibody titers in cattle 
Strong BTV-8 neutralizing antibody titers were detected three weeks after 
second vaccination in cattle immunized twice at a three-week interval with 
SubV. Titers were comparable to those induced by a commercial inactivated 
vaccine following the same vaccine regimen (2.7±0.2 and 2.9±0.5 log10 
titers/ml for SubV and CV, respectively; p=0.17) (Paper II). Neutralizing 
antibodies have been shown to be an essential component of the protective 
immune response against BTV (Huismans et al., 1987; Roy et al., 1990) and 
similar titers, ranging from 1.5-2.5 log10 TCID50, have been observed following 
vaccination with killed commercial vaccines in ruminants that were ultimately 
protected from BTV-8 challenge (Bréard et al., 2011). The induction of similar 
neutralizing antibody titers by both SubV and CV indicated that the 
experimental vaccine may induce a level of protection similar to that which has 
already been demonstrated for the commercial vaccine (Eschbaumer et al., 
2009; Gethmann et al., 2009; Wäckerlin et al., 2010; Bartram et al., 2011; 
Bréard et al., 2011). Of the three proteins included in the SubV formulation, 
VP2 is the only protein associated with the induction of virus-neutralizing 
antibodies (Huismans & Erasmus, 1981; Kahlon et al., 1983; Roy et al., 1990). 
Previous studies have demonstrated that VP5 may also play a role by 
supporting the tertiary conformation of VP2 (Cowley & Gorman, 1989; 
Mertens et al., 1989; Roy et al., 1990; DeMaula et al., 2000). Therefore, it has 
been suggested that the inclusion of VP5 with VP2 would benefit any vaccine 
(Schwartz-Cornil et al., 2008). However, since SubV induced neutralizing 
antibody titers that were equal to those induced by CV, the results indicated 
that VP2 alone and at the amount used in study II, may be sufficient to induce 
virus-neutralizing antibody titers equivalent to those attained with a 
commercial vaccine. 
In study III, serum samples were collected before second vaccination and 
then almost weekly from this time point until three weeks after BTV-8 
challenge, which enabled observation of the time course for antibody 
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development following vaccination and challenge. BTV-neutralizing 
antibodies were detected as early as one week after second vaccination in 
SubV-immunized calves, and continued to increase until one week after BTV-8 
challenge, when they stabilized (Paper III). In contrast, virus-neutralizing 
antibodies were first detected in the sera of 1/6 controls only two weeks after 
BTV-8 challenge, and although all controls eventually seroconverted three 
weeks after challenge, they remained at significantly lower titers compared to 
those of the vaccinated calves (p≤0.05). Compared to other experimental 
vaccines, the peak neutralizing antibody titers observed in this study were 
similar to those observed in ruminants following vaccination with similar 
recombinant subunit vaccines or DISC vaccines (Roy et al., 1990; Matsuo et 
al., 2011). However, the DISC vaccine was able to induce neutralizing 
antibodies after just one vaccination, perhaps due to its ability to enable 
expression of the viral proteins at the natural site of infection, much like MLVs 
(Roy et al., 2009). 
4.2.2 Induction of serum antibodies directed against VP2 (BTV-8) and NS1, 
NS2 (BTV-2) detected by ELISA 
Using cELISA, VP2-specific serum antibodies were detected after vaccination 
in animals immunized with either SubV (Papers II, III) or CV (Paper II). The 
quantity of detected VP2-specific antibodies induced by vaccination was 
greater in animals immunized by SubV than by CV. This may have been due to 
several factors, including the assay itself, which is based on the same protein 
used in SubV, to the high amount of VP2 antigen included in SubV in 
comparison with possibly lower amounts of VP2 antigen included in CV, or to 
conformational changes to the VP2 antigen during inactivation of the virus for 
inclusion in CV. The detection of VP2 antibodies is important for DIVA, 
because they can indicate serotype-specific infection or vaccination (as 
discussed in section 1.7.2). 
Specific serum IgG1 antibodies directed against NS1 and NS2 were also 
detected in cattle immunized with SubV. Levels of NS2-specific antibodies 
increased in SubV-immunized animals compared to in controls as early as 
three weeks after first vaccination (p≤0.05 for both study II, III) and both NS1- 
and NS2-specific antibody levels peaked three weeks after second vaccination 
(p≤0.01 for NS1 for both study II, III; p≤0.05 for NS2 for both study II, III). 
Since the indirect ELISA used to detect antibodies herein was based on NS1 
protein of BTV-2, and CV was of serotype 8, serotype divergence may explain 
the absence of NS1 antibodies following CV immunization in this study. 
However, both genetic and serological analyses of the protein and its encoding 
RNA segment (segment 5) have shown that NS1 is well conserved across 
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serotypes (Mecham et al., 1986; Toussaint et al., 2007; Maan et al., 2008). 
Furthermore, it has been shown in previous studies that NS1 antibodies were 
not detected in sheep following immunization with inactivated vaccines 
(Anderson et al., 1993). Therefore, it is unlikely that serotype differences could 
explain the lack of NS1 antibody response to CV. A more plausible 
explanation is that NS1-specific antibodies were simply not induced by CV, 
perhaps because NS1 was only present in low quantities in that vaccine. This 
latter explanation was supported by findings in study III, where, using a similar 
assay, specific serum antibodies to NS1 of BTV-2 were detected in 4/6 control 
calves three weeks after BTV-8 challenge, thus indicating that antibodies to 
NS1 of BTV-8 can recognize NS1 of BTV-2. 
Similarly, though the magnitude of the specific antibody response directed 
against NS2 following vaccination with CV was much lower than those 
induced by SubV, it is unlikely that serotype-specific differences in the protein 
are responsible for the weaker antibody response to CV. This was supported by 
findings in study III, in which NS2 (BTV-2)-specific IgG1 antibodies were 
detected in the serum of 5/6 non-vaccinated controls three weeks after BTV-8 
challenge. In comparison to high levels of NS2 included in SubV, the CV 
preparation likely included low original quantities of this protein since, like 
NS1, it is a primarily internal protein that is only produced during viral 
replication. Therefore, in contrast to challenge, CV induced only weak levels 
of NS2-specific antibodies. That NS2 induced any antibody production 
following immunization with CV, in contrast to NS1, may be due to several 
potential differences between the proteins, such as inherent dissimilarities in 
protein-specific immunogenicities or disparities in protein quantities following 
BTV replication for CV production. Additionally, it has previously been 
suggested that NS2 may associate with membrane proteins VP2 and VP5 
(Mertens et al., 1987), and therefore NS2 may have remained in higher final 
quantity than NS1 following clarification of BTV during CV manufacturing. 
To the best of my knowledge, the results presented in study II and III represent 
the first time that NS2-specific antibodies have been detected in vaccinated and 
infected cattle, though NS2 antibodies have been previously observed in the 
polyclonal sera of experimentally-infected rabbits (Mecham et al., 1986). 
Both NS1 and NS2 have induced specific serum antibodies in cattle, but the 
role that these antibodies may play in protection is not known. Studies in 
flaviviruses have shown that antibodies to NS proteins can provide protection 
against viral challenge, perhaps by inducing complement-mediated cytolysis or 
antibody-dependent cellular cytotoxicity through recognition of antigen 
expressed on infected cells (Kreil et al., 1998; Calvert et al., 2006; Chung et 
al., 2006; Wan et al., 2014), as reviewed by (Burton, 2002). However, whether 
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NS1 or NS2 antigens are expressed on the surface of BTV-infected cells, as 
well as other possible mechanisms of protection induced by non-neutralizing 
antibodies, should be further investigated. 
4.3 Cellular immune responses against BTV in cattle following 
vaccination and challenge 
Cellular immune responses induced by SubV and CV (study II, III) were 
measured in cattle by specific lymphocyte proliferation following ex vivo 
restimulation of PBMCs. In this work, AlamarBlue®-reagent was used to 
quantify the proliferation of cells following restimulation. This reagent works 
by changing absorbance in proportion to the number of living cells and when 
used in combination with background control stimulations, can provide low but 
specific values. The use of the alamarBlue®-reagent is simple and non-toxic, 
and the method has been demonstrated to be as reliable as alternative assays 
(Ahmed et al., 1994). This method has also been successfully utilized in other 
studies (Hägglund et al., 2011; Blodörn et al., 2014). 
4.3.1 Induction of VP2-specific lymphocyte proliferative responses 
Specific lymphocyte proliferative responses directed against VP2 were not 
detected in cattle with either SubV or CV (study II, Paper II), nor after 
modifying the protocol by increasing protein concentrations fivefold for 
restimulation (study III, Paper III). This is in contrast to results of others, 
where strong but variable CTL responses directed against VP2 were reported in 
vaccinated sheep (Andrew et al., 1995; Janardhana et al., 1999). VP2-specific 
lymphoproliferative responses were also detected following restimulation of 
spleen lymphocytes in mice (study I, Paper I). As the tertiary conformation of 
VP2 has been shown to be important (White & Eaton, 1990), conformational 
issues, as well as differences in vaccine preparation (including adjuvant, 
antigen selection and/or quantity, and route of administration), cell origin for 
stimulation (for example, PBMCs or spleen lymphocytes) or species-
differences among mice, sheep, and cattle, may provide an explanation for the 
observed differences between this study and previous reports. Although the 
lymphocyte proliferation assay was modified for study III by increasing protein 
concentrations for restimulation, some possible cellular cytotoxicity by the 
protein was observed in both studies (data not shown) which may have affected 
in vitro restimulation. Evaluation of whether experimentally-infected non-
vaccinated control calves showed lymphoproliferative responses to VP2 after 
challenge with BTV might have enabled us to conclude if a T cell response 
was induced against this protein in cattle, but this was not possible due to poor 
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viability of cells isolated one week after challenge and then stored in liquid 
nitrogen (Paper III). This could as well be further investigated by restimulating 
isolated PBMCs from naturally infected cattle with purified VP2 expressed in 
different systems, or by restimulating PBMCs from cattle vaccinated with VP2 
expressed in different systems with live or inactivated BTV. 
While it cannot be excluded that the assay needs to be further improved, the 
disparity of the results between the murine and bovine assays also highlights 
the importance of evaluating a novel vaccine in the target species. 
4.3.2 Induction of NS1-, NS2-, and UV-inactivated BTV-8 specific lymphocyte 
proliferative responses 
In study II, significantly higher lymphocyte proliferative responses directed 
against NS1, but not NS2, were observed in cattle immunized with either SubV 
or CV three weeks after second vaccination compared to controls (p≤0.01 and 
p≤0.05 for SubV and CV, respectively) (Paper II). These results were verified 
by the detection of IFN-γ in supernatants from restimulated PBMCs. IFN-γ is a 
cytokine produced by cells of the innate and adaptive immune systems, 
including natural killer (NK) cells, helper T cells (CD4+), and CTLs (CD8+), 
and its production stimulates antigen-presenting cells and upregulates their 
antigen-processing and -presenting pathways (Schroder et al., 2004). The 
detection of IFN-γ in supernatant following ex vivo restimulation of 
lymphocytes is used as an indicator of intracellular activation of type 1 T 
helper cells against viral infection (Allmendinger et al., 2010; Hägglund et al., 
2011; Hund et al., 2012). 
In study III, in addition to confirming NS1-specificity of lymphocyte 
proliferative responses in SubV-vaccinated cattle, NS2-specific 
lymphoproliferative responses were also obtained after increasing the 
concentration of NS2 recombinant protein used to restimulate isolated PBMCs 
(Paper III). A significant T cell response directed against NS2 was detected in 
all vaccinated calves three weeks after second vaccination (p≤0.05 compared to 
controls). In line with these findings, NS2 has been reported to induce CTL 
production in mice or sheep following experimental BTV vaccination or 
infection in previous studies (Jones et al., 1996, 1997). 
Another advantage of study III over study II was the opportunity to evaluate 
BTV-8-specific lymphocyte proliferative responses in experimentally infected 
animals in the biosecurity level 3 laboratory facilities at SVA. Specific 
lymphocyte proliferation to UV-inactivated BTV-8 was detected three weeks 
after second vaccination (before challenge) in vaccinated calves (p≤0.01 
compared to controls). Of the three proteins included in SubV, specific 
lymphoproliferative responses directed against only NS1 and NS2 (of BTV-2) 
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were detected. Therefore, these results suggest that a cross-serotype T cell 
response may have been induced by the NS proteins included in SubV. Based 
on the results of study II, where CV (of BTV-8) was shown to induce cross-
serotype cellular immune responses directed against NS1 (as detected by using 
NS1 of BTV-2 for in vitro restimulations), it was hypothesized that such a 
response would be observed. Further evaluation is needed to characterize the 
nature of this cross-serotype immune response induced by the NS proteins 
included in SubV. For example, it would be of value to determine if the 
observed response was based on the proliferation of helper T cells or CTLs. 
Helper T cells are able to respond to killed antigens, such as those which were 
used in the T cell assays here, because they recognize exogenous antigens 
presented on MHC class II molecules. In contrast, CTLs better recognize 
intracellular antigens presented on MHC class I (Neefjes et al., 2011). 
Therefore, helper T cells may be preferentially detected using such assays, 
even though cross-presentation of vaccine antigens or cross-priming stimulated 
by the ISCOM-matrix adjuvant (Duewell et al., 2011) may have facilitated 
CTL induction in vivo. Other assays, such as flow cytometry following 
isolation of PBMCs restimulated with BTV or BTV-infected cells (Hemati et 
al., 2009; Pérez de Diego et al., 2012), may better predict the activation and 
functional ability of CTLs, as well as helper T cells, induced by SubV 
vaccination. Additionally, it would be of value to evaluate these responses 
against BTV-2 or other serotypes, to test the cross-reactivity of the SubV-
induced T cell responses. 
The initial inclusion of the NS proteins in the design of SubV was based on 
their potential to induce cross-serotype immune responses, which could 
contribute to protection against several BTV serotypes, as has recently been 
shown for BTV (Calvo-Pinilla et al., 2012) and African horse sickness virus 
(de la Poza et al., 2013) in IFNAR(-/-) mice. Additionally, the induction of cell-
mediated immune responses by NS1 and NS2, in combination with 
neutralizing antibodies induced by VP2, may also contribute to broader vaccine 
efficacy as well as a potentially longer duration of protection, by stimulating 
diverse immune responses. Recent studies on swine influenza vaccine 
development have shown that DNA vaccines composed of variable antibody 
and conserved CTL epitopes provide greater protection against heterologous 
challenge than those composed of antibody epitopes alone (Wang et al., 2012), 
which is crucial for viruses such as influenza or BTV in which reassortments 
can occur (Shaw et al., 2012). Additionally, the induction of T cell responses 
can also contribute to the duration of protective immunity, as helper T cells can 
aid the maturation of B cells into long-lived plasma cells and memory B cells 
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(Slifka & Amanna, 2014) as well as the formation of activated CTLs into 
memory CTLs (Swain et al., 2012). 
4.4 Protective efficacy against BTV-8 challenge 
4.4.1 Clinical signs following BTV-8 challenge 
All non-vaccinated control calves showed mild clinical signs of BTV infection 
from two to fourteen days after BTV-8 challenge, including general depression 
with appetite loss, edema, nasal discharge, stiffness, and a biphasic rectal 
temperature pattern that peaked on PID4 and PID7. In contrast, three of six 
vaccinated calves demonstrated no clinical signs throughout the entire study 
and no increase in rectal temperature was detected in SubV-vaccinated animals 
after BTV-8 challenge (maximum rectal temperatures mean, SubV: 
39.1±0.1°C; Control: 40.0±0.4°C; p≤0.01). In the remaining three calves 
immunized with SubV, limited and mild clinical signs were observed on one 
day each between PID4-6, including slight serous nasal discharge in one calf 
and a stiff gait for one day in two calves. Vaccinated calves had low mean 
clinical scores that never exceeded 0.5 (Table 6, section 3.5.3).  
The clinical signs observed here were similar to those reported following 
natural or experimental infection of ruminants (Thiry et al., 2006; Di 
Gialleonardo et al., 2011; Rasmussen et al., 2013), whereas other challenge 
studies have failed to induce clinical signs in control animals (Bréard et al., 
2011; Matsuo et al., 2011). One of the BTV-8 suspensions in this study was 
passaged on KC cells, which may more closely mimic natural, Culicoides-
derived infection, and may explain the occurrence of clinical signs following 
this challenge, in contrast to studies where the challenge virus was passaged in 
mammalian cell cultures (Flanagan & Johnson, 1995; OIE, 2009). This 
influence of viral passage on experimental pathogenicity has been previously 
observed for BTV (Moulin et al., 2012) as well as other arboviruses, such as 
Schmallenberg virus (Wernike et al., 2012).  
4.4.2 Quantification of BTV RNA and detection of BTV in blood 
Viremic titers similar to previous reports of experimental BTV challenge (Di 
Gialleonardo et al., 2011; Rasmussen et al., 2013) were detected by RT-qPCR 
analysis in the blood of all controls by PID6, peaked at PID10, and remained 
stable through PID25. These results were also verified by ECE inoculation, 
where 2-4 of 5 ECE inoculated with diluted blood samples from control calves 
showed characteristic hemorrhagic signs of BTV infection and were also RT-
qPCR-positive (Ct range: 27-38) for BTV RNA. 
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In contrast, no BTV RNA was detected by RT-qPCR analysis in any SubV-
vaccinated calf before or after BTV-8 challenge through to experiment 
termination (PID25). These results were confirmed by the absence of BTV 
isolation in ECE. 
Taken together with results from clinical examinations, the experimental 
subunit vaccine presented here is a promising vaccine candidate. In contrast to 
other experimental and commercial vaccines studies, which provide or discuss 
only clinical (Calvo-Pinilla et al., 2014; Mohd Jaafar et al., 2014) or only 
virological (Matsuo et al., 2011) protection, our results show that no clinical 
BT disease was observed in cattle following SubV vaccination. Furthermore, 
SubV completely prevented the systemic replication of BTV, and thereby 
would likely prevent vector-borne transmission of the virus and bar potential 
BTV recombination in cattle (Roy et al., 2009). 
4.5 DIVA compliancy based on serotype-specific and pan-BTV 
ELISAs 
The companion DIVA tests of SubV are based on two parameters: i) the 
detection of VP2 antibodies, which identifies serotype-specific BTV infection 
or vaccination; and ii) the detection of VP7 antibody levels, which 
differentiates between infection (followed by BTV replication and potential 
transmission) of any serotype and vaccination with SubV (Figure 7).  
 
Figure 7. Schematic illustration of the DIVA concept for SubV compared to a classic vaccine. 
Blue rectangles indicate positive samples based on the VP2- or VP7-specific ELISA test used for 
evaluating corresponding antibodies and conditions. Animals with "transmissible BTV" are not 
protected against BTV infection (thus BTV replication and potential transmission can occur). 
Based on VP2 antibody detection, calves were seropositive for BTV-8 
infection within three weeks following vaccination with CV (Paper II) or 
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SubV (Paper II, Paper III), or following experimental BTV-8 infection (Paper 
III) (Figure 8). 
In study II, VP7-specific serum antibodies were detected by sandwich 
ELISA, only in animals immunized with CV (Paper II). In study III, high 
levels of VP7-specific antibodies were detected by cELISA in the sera of all 
controls after BTV-8 challenge (Paper III, Figure 8). VP7-specific antibodies 
were also detected by cELISA in the sera of SubV-vaccinated calves after 
challenge, but these levels were low and could therefore be distinguished from 
non-vaccinated controls. Since antibodies to VP7 were detected following 
vaccination with a killed vaccine in study II (Figure 8), as also reported 
previously (Gethmann et al., 2009), and because no live BTV or BTV RNA 
was detected in the blood of any SubV-vaccinated calf following BTV-8 
challenge in study III, the presence of VP7-specific antibodies induced in the 
SubV-vaccinated calves was probably due to the presence of antigen in the 
challenge virus suspensions or to local replication at the site of injection. This 
contrasts the systemic virus replication detected in controls, which is likely 
required to enable virus transmission. Based on the results of study III, the cut-
off was defined to be at ≥75% to suggest systemic BTV replication. This 
indicates that SubV is DIVA compliant and confirms results that animals in 
which BTV-8 can replicate can be identified using the cELISA as early as two-
to-three weeks following infection (Gethmann et al., 2009). This cut-off would 
likely be lower under field conditions or perhaps following experimental 
challenge with infected Culicoides midges (Pages et al., 2014), and thus must 
be validated with samples from naturally-infected animals. 
VP7 was chosen in this project as the DIVA marker because it has been 
used in Europe to indicate BTV infection irrespective of serotype and because 
the immune responses it induces can be detected at an early stage (Zhou et al., 
2001; Bréard et al., 2011) and yet do not appear to be essential for protection 
(Roy et al., 1990; Wade-Evans et al., 1996; Mohd Jaafar et al., 2014). There 
are several commercially-available VP7-based ELISAs available in Europe, 
including assays designed for use with bulk milk samples (Kramps et al., 
2008), which could be a quick and effective way to perform surveillance in 
non-endemic countries. In study II, a sandwich ELISA was chosen because it 
had been shown to be very sensitive, particularly for detecting antibodies 
induced by inactivated vaccines (Oura et al., 2009) such as CV included in that 
study. However, VP7 antibody levels detected by these assays have been 
reported to decrease after two or three weeks in some experimentally-infected 
ruminants, likely due to a lower assay sensitivity to IgG compared to IgM 
(Eschbaumer et al., 2011). Therefore, in study III, a cELISA was used instead 
in order to follow recommendations for safe serological diagnoses and to limit 
 78 
specificity issues of the sandwich ELISA based on time of sampling 
(Eschbaumer et al., 2011), which could be problematic under surveillance 
conditions. 
Figure 8. Specific serum antibodies against VP2 of BTV-8 and VP7 of BTV for DIVA 
compliancy of SubV in studies II and III. In study II (blue), animals were immunized at 0 and 3 
weeks (black arrows) with PBS (Control 1-5), a commercial inactivated vaccine (CV 1-5), or the 
experimental subunit vaccines (SubV 1-5), but not challenged with virus. In study II (blue), no 
animals were challenged with virus. In study III (green), animals were immunized at 0 and 3 
weeks (black arrows) with the experimental subunit vaccine (SubV 6-11) or adjuvant alone 
(Control 6-11), then challenged with BTV-8 at 6 weeks (white arrow). A cELISA was used to 
detect VP2-specific antibodies in both studies, while a sandwich ELISA and a cELISA were used 
to detect VP7-specific antibodies in study II and study III, respectively. Gray boxes indicate 
seropositive ELISA results while white boxes indicate seronegative ELISA results. 
 79 
In addition to VP7, other proteins, such as NS1 and NS3, have also been 
suggested as potential DIVA markers, particularly in combination with 
inactivated vaccines, because they are only produced during BTV replication 
(Anderson et al., 1993; Barros et al., 2009). However, since these proteins are 
not actively removed from CV, as is performed for certain foot and mouth 
disease vaccines (Paton et al., 2006), it is possible that enough antigen would 
remain such that some NS1- or NS3-specific antibodies would be induced by 
the vaccine; this could complicate or even impair any such DIVA capability. In 
fact, antibodies directed against NS1 were detected in 14 of 56 cows 
vaccinated with inactivated BTV vaccines in the northern area of vaccination 
in Sweden, where BTV was not known to circulate (J.F. Valarcher and L. 
Renström, personal observation). 
 
In conclusion, this thesis work began with a pool of five immunologically-
relevant recombinant BTV proteins, that was narrowed down to three proteins 
suitable for subunit vaccine production. In combination with an ISCOM-matrix 
adjuvant, these proteins were shown to induce humoral and cellular immune 
responses in cattle that were similar to those induced by a commercial 
inactivated vaccine. Finally, the experimental vaccine was shown to provide 
complete clinical and virological protection against virulent BTV-8 challenge 
in calves, while also satisfying the DIVA requirement through the use of 
existing diagnostic assays. 
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5 Concluding remarks 
Veterinary and human vaccine development offers an avenue for increasing 
knowledge about the pathogen of interest, while simultaneously providing a 
potential real-life application for those results. Here, we present a promising 
subunit vaccine candidate against BTV-8, while also contributing to BTV 
knowledge regarding the protein-specificity of immune responses in cattle. 
 
Ø The experimental subunit vaccine provided virological and clinical 
protection against BTV-8 infection in calves. This protection was likely 
mediated by the induction of strong neutralizing antibody titers directed 
against VP2 and cross-serotype cellular immune responses to NS1 and NS2. 
Serum antibodies to VP2, NS1, and NS2 were also induced by both the 
experimental subunit vaccine and by BTV-8 challenge.  
Ø The measurement of specific serum antibodies to VP7 enabled the 
differentiation of infected animals in which the virus replicated to levels 
that were likely to be transmissible, from the vaccinated animals that were 
protected against infection. Therefore, the detection of VP2- and VP7-
specific antibodies by ELISA could be used as DIVA companion tests with 
the experimental subunit vaccine developed in this thesis work. These 
companion tests will additionally allow the detection of BTV infection with 
a serotype against which SubV does not protect. 
Ø The experimental subunit vaccine induced immune responses that were 
comparable to those induced by a classic commercial inactivated vaccine. 
By evaluating the experimental vaccine in comparison with the commercial 
vaccine, it was possible to get an indication of the potential protective 
efficacy of the experimental vaccine before performing a challenge study. 
Furthermore, these studies shed light on the specific immune responses 
induced by the inactivated vaccine in cattle; for example, the inactivated 
vaccine induced cross-serotype cellular immune responses directed against 
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NS1 of BTV-2 in cattle, as well as antibodies to VP2, NS2, and VP7, but 
not to recombinant NS1. 
Ø Species differences in T cell responses induced by recombinant VP2 were 
observed. In particular, this VP2 induced specific lymphocyte proliferative 
responses in mice, but similar responses could not be detected in vaccinated 
cattle. These responses need to be evaluated in cattle following natural BTV 
infection or alternatively following BTV vaccination and restimulation of 
isolated PBMCs with VP2 produced in several different expression 
systems. The species differences observed in this thesis work highlight the 
importance of evaluating candidate vaccines in the target species. 
Ø It was possible to produce and purify VP2 of BTV-8 and NS1 and NS2 of 
BTV-2 in sufficient quantity for vaccine use in experimental settings. 
Furthermore, these recombinant proteins were stable for at least 1.5 years at 
+4°C and -80°C, and each induced humoral and cellular immune responses 
in mice which indicated that they might be immunogenic in cattle. 
Therefore, they were suitable choices for rational subunit vaccine design. 
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6 Future perspectives 
BTV is one of the most well characterized orbiviruses and many important, 
pioneering contributions to the study of veterinary infectious diseases have 
been made through BTV-related research. However, gaps in knowledge still 
remain. For example, much of the in vivo immunological studies have been 
performed in sheep. Sheep are important targets for vaccination as they are 
often most severely clinically affected by BTV infection. However, several 
studies have indicated the ease with which the segmented BTV genome can 
reassort (Oberst et al., 1985, 1987; Stott et al., 1987; Shaw et al., 2012), and 
since cattle act as the virus's main amplifying host, they are also important 
targets for vaccination in areas where the virus is not endemic or where several 
BTV serotypes co-circulate. It is crucial that more immunological research is 
performed in cattle. 
Through the work presented in this thesis, we have begun to study the 
immune responses induced by purified VP2, NS1, and NS2 in cattle. We have 
also demonstrated that an experimental subunit vaccine composed of these 
three recombinant proteins provided protection against BTV-8 infection. 
However, though the concept of this vaccine is working, it remains to be 
optimized, which may be achieved by answering the following questions: 
Ø Are each of the proteins necessary for a successful vaccine and can their 
quantities be reduced without losing protective efficacy? To answer this 
question, the individual protective contributions of each protein, and 
particularly of NS1 and NS2, should be clarified and different 
formulations should be tested experimentally. For example, animals 
vaccinated with SubV (or with formulations including both or only one 
NS protein) could be challenged with BTV-2 or with another BTV 
serotype, and then the  protective efficacy evaluated in order to verify if 
these proteins do indeed provide cross-serotype protection. Reducing 
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protein number or quantity could decrease the cost of vaccine 
production. 
Ø Can the production and/or purification of these proteins be optimized to 
give higher yields, without losing safety, stability, and immunogenicity? 
This could also reduce the cost, as well as time, of vaccine production. 
Other systems that have recently been used with success in recombinant 
protein production for experimental veterinary vaccines include yeast 
(Shin & Yoo, 2013), plant-based (Guerrero-Andrade et al., 2006), or 
silkworm-baculovirus (Li et al., 2008) expression systems. Although it 
was possible to purify these three proteins using a His-tagged system, 
experimenting with other affinity tags, such as a GST tag, may yield 
better results. 
Ø Would a different adjuvant increase the efficacy of this vaccine, 
especially if protein quantities are reduced? There is an increasing 
number of adjuvants available for veterinary vaccine use. The adjuvant 
effect might vary according to the antigens included in the vaccine 
(Blodörn et al., 2014). For example, testing water-oil emulsions or CpG 
adjuvants (Singh & O’Hagan, 2003; Bode et al., 2011) might induce 
strong T cell responses against the NS proteins and possibly also against 
VP2. 
Ø What is the length of protective duration provided by the experimental 
vaccine? It has been demonstrated that the experimental vaccine 
produces diverse immune responses, which may provide a long duration 
of immunity, indicated by the magnitude of virus neutralizing antibody 
responses and the additional induction of T cell responses. This is 
especially important for cattle compared to other shorter-lived 
agricultural animals such as pigs or chickens and could not only reduce 
the cost of vaccination (by decreasing the required frequency of re-
vaccination) but also potentially enable eradication programs based on 
vaccination. The duration of immunity following vaccination needs to 
be determined, both for the recombinant subunit vaccine presented in 
this thesis and for any optimized version of that vaccine. 
Ø Would this experimental vaccine be equally effective against BTV-8 
challenge in sheep, as observed for cattle? It is uncommon to design a 
vaccine against BTV specifically for use in cattle, rather than first 
evaluating the experimental vaccine in smaller (and less expensive) 
animals such as sheep. We chose to do so because cattle play an 
important role in maintaining BTV in circulation as its primary 
amplifying host and they are also present in higher numbers than sheep 
in Sweden. Furthermore, the BTV-8 outbreak in northern Europe was 
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unusual because in contrast to other BTV strains or serotypes, it caused 
clinical signs in cattle and goats. Nonetheless, as sheep remain an 
important piece of the BTV puzzle it would be essential to determine 
whether this experimental vaccine would be as equally efficacious 
against BTV-8 challenge in sheep as in cattle. It would also be of 
interest to decrease the quantity of protein in order to decrease the cost 
of vaccination in small ruminants. 
 
In addition to optimizing the experimental vaccine, its design can also be 
further developed. One advantage of this experimental subunit vaccine's design 
is its potential adaptability to other BTV serotypes, based on the inclusion of 
serotypically-conserved NS1 and NS2 proteins. The adaptability of this subunit 
vaccine could be tested by simply exchanging the VP2 of BTV-8 with VP2 of 
another serotype, since it is possible that the vaccine may provide protection 
against other serotypes. 
Developing a multi-serotype BTV vaccine, by including VP2 from different 
serotypes, and evaluating potential cross-protection against those serotypes, 
would be an important line of investigation for the future. Studies by Jeggo and 
colleagues, which show some cross-neutralization among BTV serotypes, have 
provided support for speculation that there may be a minimum number of BTV 
serotypes needed in a multivalent vaccine to provide broad protection (Jeggo & 
Wardley, 1982a; Jeggo et al., 1983, 1984b). It would be interesting to evaluate 
this, first by identifying conserved epitopes, and then experimentally in vaccine 
studies. Additionally, it could be promising to experimentally study whether a 
multiple-formulation vaccine regimen, including several VP2 of different 
serotypes for each vaccination, could offer broad protection across several 
serotypes. It has recently been shown that VP2 from at least six different 
African horse sickness virus serotypes can be expressed in a mult-loci 
baculovirus expression system (Kanai et al., 2013), which could be an 
advantageous approach for producing VP2 of BTV for a potential 
multiserotype subunit vaccine. 
Finally, it was shown through the last two studies presented in this thesis 
that the experimental subunit vaccine is DIVA compliant under the study 
conditions using VP2- and VP7-specific ELISAs. The challenge conditions in 
the final study were strong, and as animals were subcutaneously inoculated 
with BTV-8, the challenge route differed from the natural route of infection. 
The DIVA compliancy of the experimental vaccine should be further evaluated 
in a larger number of animals under field conditions. Thereby, the cut-off 
defined in this thesis could be adjusted in the field following natural infection. 
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In summary, this thesis presents the first stages in the development and 
evaluation of a novel, rationally-designed recombinant subunit DIVA vaccine 
against BTV-8. These results provide a promising foundation for further 
optimizing and even developing the experimental vaccine, while 
simultaneously contributing to the basic science knowledge regarding the host-
pathogen interactions required to develop efficient BTV vaccines. 
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